<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        1111246176
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2002
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        FLOZAK
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        FLUOXETINE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Capsule, hard
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        30
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Bottle
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        Generic
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 30°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        76
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="RIYADH PHARMA" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 407]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            RIYADH PHARMA
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        N06AB03
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>FLOZAK 20 mg capsules contain the active substance fluoxetine, which is one of a group of medicines called selective serotonin re-uptake inhibitors (SSRI) antidepressants. &nbsp;</p><p><strong>This medicine is used to treat the following conditions: </strong></p><p><strong><em>Adults</em></strong>:</p><ul><li>Major depressive episodes</li><li>Obsessive-compulsive disorder</li><li>Bulimia nervosa: FLOZAK is used alongside psychotherapy for the reduction of binge-eating and purging</li></ul><p><strong><em>Children and adolescents aged 8 years and above</em></strong><strong>: </strong></p><ul><li>Moderate to severe major depressive disorder, if the depression does not respond to psychological therapy after 4-6 sessions. FLOZAK should be offered to a child or young person with moderate to severe major depressive disorder <strong>only </strong>in combination with psychological therapy.</li></ul><p><strong>How FLOZAK works </strong></p><p>Everyone has a substance called serotonin in their brain. People who are depressed or have obsessive-compulsive disorder or bulimia nervosa have lower levels of serotonin than others have. It is not fully understood how FLOZAK and other SSRIs work but they may help by increasing the level of serotonin in the brain.</p><p>Treating these conditions is important to help you get better. If it&rsquo;s not treated, your condition may not go away and may become more serious and more difficult to treat.</p><p>You may need to be treated for a few weeks or months to ensure that you are free from symptoms.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p><strong>EIGHT IMPORTANT THINGS YOU NEED TO KNOW ABOUT FLOZAK</strong></p><ul><li><strong>FLOZAK treats depression and anxiety disorders. </strong></li></ul><p>Like all medicines, it can have unwanted effects. It is therefore important that you and your doctor weigh up the benefits of treatment against the possible unwanted effects, before starting treatment.</p><ul><li><strong>FLOZAK is not for use in children and adolescents under 18. </strong>See section 2,</li></ul><p><em>Children and adolescents aged 8 to 18 years. </em></p><ul><li><strong>FLOZAK will not work straight away. </strong>Some people taking antidepressants feel worse before feeling better. Your doctor should ask to see you again a couple of weeks after you first start treatment. Tell your doctor if you have not started feeling better.</li></ul><p>&nbsp;See section 3, <em>How to take </em>FLOZAK<strong><em> </em></strong><em>hard capsules. </em></p><ul><li><strong>Some people who are depressed or anxious think of harming or killing </strong></li></ul><p><strong>Themselves, </strong>if you start to feel worse, or think of harming or killing yourself.</p><p><strong>See your doctor or go to a hospital straight away. </strong>See section 2.</p><ul><li><strong>Do not stop taking FLOZAK without talking to your doctor.</strong></li></ul><p><strong>&nbsp;</strong>If you stop taking FLOZAK<strong><em> </em></strong>suddenly or miss a dose, you may get withdrawal effects. See section 3 for further information. &nbsp;</p><ul><li><strong>If you feel restless and feel like you cannot sit or stand still, tell your doctor. </strong></li></ul><p>Increasing the dose of FLOZAK<strong><em> </em></strong>may make these feelings worse.</p><p>See section 4, <em>Possible side-effects. </em></p><ul><li><strong>Taking some other medicines with FLOZAK can cause problems. </strong></li></ul><p>You may need to talk to your doctor. See section 2, <em>Taking other medicines. </em></p><ul><li><strong>If you are pregnant or planning to get pregnant, </strong>talk to your doctor. See section 2,</li></ul><p>&nbsp;Pregnancy, breast-feeding and fertility.</p><p><strong>Do not take </strong><strong>FLOZAK</strong><strong> if you are: </strong></p><ul><li>Allergic to fluoxetine or any of the other ingredients of this medicine (listed in section 6). If you develop a rash or other allergic reactions (like itching, swollen lips or face or shortness of breath), stop taking the capsules straight away and contact your doctor immediately.</li><li>taking other medicines known as irreversible, non-selective monoamine oxidase inhibitors (MAOIs), since serious or even fatal reactions can occur (e.g. iproniazid used to treat depression).</li></ul><p>Treatment with FLOZAK should only be started at least 2 weeks after discontinuation of an irreversible, non-selective MAOI.</p><p><strong>Do not take</strong> any irreversible, non-selective MAOIs for at least 5 weeks after you stop taking FLOZAK. If FLOZAK has been prescribed for a long period and/or at a high dose, a longer interval needs to be considered by your doctor.</p><ul><li>Taking metoprolol (to treat heart failure) since there is an increased risk of your heart beat becoming too slow.</li></ul><p><strong>Warnings and precautions </strong></p><p>Talk to your doctor or pharmacist before taking FLOZAK if any of the following applies to you:</p><ul><li>heart problems;</li><li>Appearance of fever, muscle stiffness or tremor, changes in your mental state like confusion, irritability and extreme agitation; you may suffer from the so-called &ldquo;serotonin syndrome&rdquo; or &ldquo;neuroleptic malignant syndrome&rdquo;. Although this syndrome occurs rarely it may result in potentially life threatening conditions; contact your doctor immediately, since FLOZAK might need to be discontinued.</li><li>mania now or in the past; if you have a manic episode, contact your doctor immediately because FLOZAK might need to be discontinued;</li><li>history of bleeding disorders or appearance of bruises or unusual bleeding;or if you are pregnant (see &lsquo;Pregnancy&rsquo;)</li><li>ongoing treatment with medicines that thin the blood (see &lsquo;<em>Other medicines and </em>FLOZAK );</li><li>Epilepsy or fits. If you have a fit (seizures) or experience an increase in seizure frequency, contact your doctor immediately; FLOZAK might need to be discontinued;</li><li>ongoing ECT (electro-convulsive therapy);</li><li>ongoing treatment with tamoxifen (used to treat breast cancer) (see &lsquo;<em>Other medicines and </em>FLOZAK <em>); </em></li><li>Starting to feel restless and cannot sit or stand still (akathisia). Increasing your dose of FLOZAK may make this worse;</li><li>diabetes (your doctor may need to adjust your dose of insulin or other antidiabetic treatment);</li><li>liver problems (your doctor may need to adjust your dosage);</li><li>low resting heart-rate and/or if you know that you may have salt depletion as a result of prolonged severe diarrhea and vomiting (being sick) or usage of diuretics (water tablets);</li><li>ongoing treatment with diuretics (water tablets), especially if you are elderly;</li><li>glaucoma (increased pressure in the eye);</li></ul><p><strong>Thoughts of suicide and worsening of your depression or anxiety disorder. </strong></p><p>If you are depressed and/or have anxiety disorders you can sometimes have thoughts of harming or killing yourself. These may be increased when first starting antidepressants, since these medicines all take time to work, usually about two weeks but sometimes longer.</p><p>You may be more likely to think like this:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you have previously had thoughts about killing or harming yourself.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; If you are a young adult. Information from clinical trials has shown an increased risk of suicidal behavior in adults aged less than 25 years with psychiatric conditions who were treated with an antidepressant.</p><p><strong>If you have thoughts of harming or killing yourself at any time, contact your doctor or go to a hospital straight away. </strong></p><p><strong>You may find it helpful to tell a relative or close friend </strong>that you are depressed or have an anxiety disorder, and ask them to read this leaflet. You might ask them to tell you if they think your depression or anxiety is getting worse, or if they are worried about changes in your behavior.</p><p><strong><em>Children and adolescents aged 8 to 18 years: </em></strong></p><p>Patients under 18 have an increased risk of side-effects such as suicide attempt, suicidal thoughts and hostility (predominantly aggression, oppositional behavior and anger) when they take this class of medicines. FLOZAK should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes (in combination with psychological therapy) and it should not be used to treat other conditions.</p><p>Additionally, only limited information concerning the long-term safety of FLOZAK on growth, puberty, mental, emotional and behavioral development in this age group is available. Despite this, and if you are a patient under 18, your doctor may prescribe FLOZAK for moderate to severe major depressive episodes, in combination with psychological therapy, because he/she decides that this is in your best interests. If your doctor has prescribed FLOZAK for a patient under 18 and you want to discuss this, please go back to your doctor. You should inform your doctor if any of the symptoms listed above develop or worsen when patients under 18 are taking FLOZAK.</p><p>FLOZAK should not be used in the treatment of children under the age of 8 years.</p><p><strong>Other medicines and FLOZAK</strong></p><p>Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines.</p><p><strong>Do not take FLOZAK with: </strong></p><ul><li>Certain irreversible, non-selective monoamine oxidase inhibitors (MAOIs) some used to treat depression. Irreversible, non-selective MAOIs must not be used with FLOZAK as serious or even fatal reactions (serotonin syndrome) can occur (see section &ldquo;<em>Do not take FLOZAK&rdquo;</em>). Treatment with FLOZAK should only be started at least 2 weeks after discontinuation of an irreversible, non-selective MAOI (for instance tranylcypromine). Do not take any irreversible, non-selective MAOIs for at least 5 weeks after you stop taking FLOZAK. If FLOZAK has been prescribed for a long period and/or at a high dose, a longer interval than 5 weeks may need to be considered by your doctor.</li><li>Metoprolol when used for heart failure; there is an increased risk of your heart beat becoming too slow.</li></ul><p><strong>FLOZAK may affect the way the following medicines work (interaction): </strong></p><ul><li><strong>Tamoxifen</strong> (used to treat breast cancer); because FLOZAK may change the blood levels of this drug, resulting in the possibility of a reduction in the effect of tamoxifen, your doctor may need to consider prescribing a different antidepressant treatment.</li><li><strong>Monoamine oxidase inhibitors A</strong> (MAOI-A) including moclobemide, linezolid (an antibiotic) and methylthioninium chloride (also called methylene blue used to &lt;indication(s) authorized in member state&gt;): due to the risk of serious or even fatal reactions (called serotonin syndrome). Treatment with fluoxetine can be started the day after stopping treatment with reversible MAOIs but the doctor may wish to monitor you carefully and use a lower dose of the MAOI-A drug.</li><li><strong>Mequitazine</strong> (for allergies); because taking this drug with FLOZAK may increase the risk of changes in the electrical activity of the heart.</li><li><strong>Phenytoin</strong> (for epilepsy); because FLOZAK may influence the blood levels of this drug, your doctor may need to introduce phenytoin more carefully and carry out check-ups when given with FLOZAK.</li><li><strong>Lithium, selegiline, St. John&rsquo;s Wort, tramadol</strong> (a painkiller), <strong>triptans</strong> (for migraine) <strong>and tryptophan</strong>; there is an increased risk of mild serotonin syndrome when these drugs are taken with FLOZAK. Your doctor will carry out more frequent check-ups.</li><li>medicines that may affect the heart&rsquo;s rhythm, e.g. <strong>Class IA and III antiarrhythmics, antipsychotics</strong> (e.g. phenothiazine derivatives, pimozide, haloperidol), <strong>tricyclic antidepressants</strong>, certain <strong>antimicrobial agents</strong> (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine), <strong>anti-malaria treatment</strong> particularly halofantrine or certain <strong>antihistamines </strong>(astemizole, mizolastine), because taking one or more of these drugs with FLOZAK may increase the risk of changes in the electrical activity of the heart.</li><li><strong>Anti-coagulants</strong> (such as warfarin), <strong>NSAID</strong> (such as ibuprofen, diclofenac), <strong>aspirin</strong> and <strong>other medicines which can thin the blood</strong> (including clozapine, used to treat certain mental disorders). FLOZAK may alter the effect of these medicines on the blood. If FLOZAK treatment is started or stopped when you are taking warfarin, your doctor will need to perform certain tests, adjust your dose and check on you more frequently.</li><li><strong>Cyproheptadine</strong> (for allergies); because it may reduce the effect of FLOZAK.</li><li><strong>Drugs that lower sodium levels in the blood</strong> (including, drug that causes increase in urination, desmopressin, carbamazepine and oxcarbazepine); because these drugs may increase the risk of sodium levels in the blood becoming too low when taken with FLOZAK.</li><li><strong>Anti-depressants</strong> such as tricyclic anti-depressants, other selective serotonin reuptake inhibitors (SSRIs) or bupropion, <strong>mefloquine</strong> or <strong>chloroquine</strong> (used to treat malaria), tramadol (used to treat severe pain) or <strong>anti-psychotics</strong> such as phenothiazines or butyrophenones; because FLOZAK may increase the risk of seizures when taken with these medicines.</li><li><strong>Flecainide</strong>, <strong>propafenone</strong>, <strong>nebivolol</strong> or <strong>encainide</strong> (for heart problems), <strong>carbamazepine</strong> (for epilepsy), <strong>atomoxetine</strong> or <strong>tricyclic antidepressants</strong> (for example <strong>imipramine</strong>, <strong>desipramine</strong> and <strong>amitriptyline</strong>) or <strong>risperidone</strong> (for schizophrenia); because FLOZAK may possibly change the blood levels of these medicines, your doctor may need to lower their dose when administered with FLOZAK.</li></ul><p><strong>FLOZAK with food, drink and alcohol </strong></p><ul><li>You can take FLOZAK with or without food, whatever you prefer.</li><li>You should avoid alcohol while you are taking this medicine.</li></ul><p><strong>Pregnancy, breast-feeding and fertility </strong></p><p>If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.</p><p><strong><em>Pregnancy </em></strong></p><p>Talk to your doctor as soon as possible if you&#39;re pregnant, if you might be pregnant, or if you&#39;re planning to become pregnant.</p><p>If you take FLOZAK near the end of your pregnancy there may be an increased risk of heavy vaginal bleeding shortly after birth, especially if you have a history of bleeding disorders. Your doctor or midwife should be aware that you are taking FLOZAK so they can advise you.</p><p>In babies whose mothers took fluoxetine during the first few months of pregnancy, there have been some reports suggesting an increased risk of birth defects affecting the heart. In the general population, about 1 in 100 babies are born with a heart defect. This increased to about 2 in 100 babies in mothers who took fluoxetine. You and your doctor may decide that it is better for you to gradually stop taking FLOZAK while you are pregnant. However, depending on your circumstances, your doctor may suggest that it is better for you to keep taking FLOZAK.</p><p>When taken during pregnancy, particularly in the last 3 months of pregnancy, medicines like fluoxetine may increase the risk of a serious condition in babies, called persistent pulmonary hypertension of the newborn (PPHN), making the baby breathe faster and appear bluish. These symptoms usually begin during the first 24 hours after the baby is born. If this happens to your baby, you should contact your midwife and/or doctor immediately.</p><p>Caution should be exercised when used during pregnancy, especially during late pregnancy or just before giving birth since the following effects have been reported in newborn children: irritability, tremor, muscle weakness, persistent crying, and difficulty in sucking or in sleeping.</p><p><strong><em>Breast-feeding </em></strong></p><p>Fluoxetine is excreted in breast milk and can cause side effects in babies. You should only breast-feed if it is clearly necessary. If breast-feeding is continued, your doctor may prescribe a lower dose of fluoxetine.</p><p><strong><em>Fertility </em></strong></p><p>Fluoxetine has been shown to reduce the quality of sperm in animal studies. Theoretically, this could affect fertility, but impact on human fertility has not been observed as yet.</p><p><strong>Driving and using machines </strong></p><p>Psychotropic drugs such as FLOZAK may affect your judgment or co-ordination. Do not drive or use machinery until you know how FLOZAK affects you.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure. Do not take more capsules than your doctor tells you.</p><p>Swallow the capsules with a drink of water. Do not chew the capsules.</p><p><strong><em>Adults: </em></strong></p><p>The recommended dose is:</p><ul><li><strong>Depression: </strong>The recommended dose is 1 capsule (20 mg) daily. Your doctor will review and adjust your dosage if necessary within 3 to 4 weeks of the start of treatment. If required, the dosage can be gradually increased up to a maximum of 3 capsules (60 mg) daily. The dose should be increased carefully to ensure that you receive the lowest effective dose. You may not feel better immediately when you first start taking your medicine for depression. This is usual because an improvement in depressive symptoms may not occur until after the first few weeks. Patients with depression should be treated for at least 6 months.</li><li><strong>Bulimia nervosa: </strong>The recommended dose is 3 capsules (60 mg) daily.</li><li><strong>Obsessive-compulsive disorder: </strong>The recommended dose is 1 capsule (20 mg) daily. Your doctor will review and adjust your dosage if necessary after 2 weeks of treatment. If required, the dosage can be gradually increased up to a maximum of 3 capsules (60 mg) daily. If no improvement is noted within 10 weeks, your doctor will reconsider your treatment.</li></ul><p><strong><em>Use in children and adolescents aged 8 to 18 years with depression: </em></strong></p><p>Treatment should be started and be supervised by a specialist. The starting dose is 10 mg/day (given as 2.5 ml of FLOZAK oral solution). After 1 to 2 weeks, your doctor may increase the dose to 20 mg/day. The dose should be increased carefully to ensure that you receive the lowest effective dose. Lower weight children may need lower doses. If there is a satisfactory response to treatment, your doctor will review the need for continuing treatment beyond 6 months. If you have not improved within 9 weeks, your doctor will reassess your treatment.</p><p><strong><em>Elderly: </em></strong></p><p>Your doctor will increase the dose with more caution and the daily dose should generally not exceed 2 capsules (40 mg). The maximum dose is 3 capsules (60 mg) daily.</p><p><strong><em>Liver impairment: </em></strong></p><p>If you have a liver problem or are using other medication that might affect FLOZAK, your doctor may decide to prescribe a lower dose or tell you to use FLOZAK every other day.</p><p><strong>If you take more FLOZAK</strong> <strong>than you should </strong></p><ul><li>If you take too many capsules, go to your nearest hospital emergency department (or casualty) or tell your doctor straight away.</li><li>Take the pack of FLOZAK with you if you can.</li></ul><p>Symptoms of overdose include: nausea, vomiting, seizures, heart problems (like irregular heart beat and cardiac arrest), lung problems and change in mental condition ranging from agitation to coma.</p><p><strong>If you forget to take FLOZAK</strong></p><ul><li>If you miss a dose, do not worry. Take your next dose the next day at the usual time. Do not take a double dose to make up for a forgotten dose.</li><li>Taking your medicine at the same time each day may help you to remember to take it regularly.</li></ul><p><strong>If you stop taking FLOZAK</strong></p><ul><li><strong>Do not </strong>stop taking FLOZAK without asking your doctor first, even when you start to feel better. It is important that you keep taking your medicine.</li><li>Make sure you do not run out of capsules.</li></ul><p>You may notice the following effects (withdrawal effects) when you stop taking FLOZAK : dizziness; tingling feelings like pins and needles; sleep disturbances (vivid dreams, nightmares, inability to sleep); feeling restless or agitated; unusual tiredness or weakness; feeling anxious; nausea/ vomiting (feeling sick or being sick); tremor (shakiness); headaches.</p><p>Most people find that any symptoms on stopping FLOZAK are mild and disappear within a few weeks. If you experience symptoms when you stop treatment, contact your doctor.</p><p>When stopping FLOZAK, your doctor will help you to reduce your dose slowly over one or two weeks - this should help reduce the chance of withdrawal effects.</p><p>If you have any further questions on the use of this medicine, ask your doctor or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p style="text-align:justify">Like all medicines, this medicine can cause side effects, although not everybody gets them.</p><ul><li>If you have thoughts of harming or killing yourself at any time, <strong>contact your doctor or go to a hospital straight away </strong>(see Section 2).</li><li>If you get a rash or allergic reaction such as itching, swollen lips/tongue or wheezing/shortness of breath, <strong>stop taking the capsules straight away and tell your doctor immediately. </strong></li><li>If you feel restless and cannot sit or stand still, you may have akathisia; increasing your dose of FLOZAK may make you feel worse. If you feel like this, <strong>contact your doctor. </strong></li><li><strong>Tell your doctor immediately </strong>if your skin starts to turn red or you develop a varied skin reaction or your skin starts to blister or peel. This is very rare.</li></ul><p>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; The most frequent sides effects (very common side effects that may affect more than 1 user in 10) are insomnia, headache, diarrhea, feeling sick (nausea) and fatigue.</p><p>Some patients have had:</p><ul><li>a combination of symptoms (known as &ldquo;serotonin syndrome&rdquo;) including unexplained fever with faster breathing or heart rate, sweating, muscle stiffness or tremor, confusion, extreme agitation or sleepiness (only rarely);</li><li>feelings of weakness, drowsiness or confusion mostly in elderly people and in (elderly) people taking diuretics (water tablets);</li><li>prolonged and painful erection;</li><li>irritability and extreme agitation;</li><li>Heart problems, such as fast or irregular heart rate, fainting, collapsing or dizziness upon standing which may indicate abnormal functioning of the heart rate.</li></ul><p><strong>If you have any of the above side effects, you should tell your doctor immediately. </strong></p><p>&nbsp;</p><p>The following side effects have also been reported in patients taking FLOZAK:</p><p><strong>Common </strong>(may affect up to 1 in 10 people)</p><ul><li>not feeling hungry, weight loss</li><li>nervousness, anxiety</li><li>restlessness, poor concentration</li><li>feeling tense</li><li>decreased sex drive or sexual problems (including difficulty maintaining an erection for sexual activity)</li><li>sleep problems, unusual dreams, tiredness or sleepiness</li><li>dizziness</li><li>change in taste</li><li>uncontrollable shaking movements</li><li>blurred vision</li><li>rapid and irregular heartbeat sensations</li><li>flushing</li><li>yawning</li><li>indigestion, vomiting</li><li>dry mouth</li><li>rash, urticaria, itching</li><li>excessive sweating</li><li>joint pain</li><li>passing urine more frequently</li><li>unexplained vaginal bleeding</li><li>feeling shaky or chills</li></ul><p><strong>&nbsp;</strong></p><p><strong>Uncommon </strong>(may affect up to 1 in 100 people)</p><ul><li>feeling detached from yourself</li><li>strange thinking</li><li>abnormally high mood</li><li>orgasm problems</li><li>thoughts of suicide or harming yourself</li><li>teeth grinding</li><li>muscle twitching, involuntary movements or problems with balance or co-ordination</li><li>memory impairment</li><li>enlarged (dilated) pupils</li><li>ringing in the ears</li><li>low blood pressure</li><li>shortness of breath</li><li>nose bleeds</li><li>difficulty swallowing</li><li>hair loss</li><li>increased tendency to bruising</li><li>unexplained bruising or bleeding</li><li>cold sweat</li><li>difficulty passing urine</li><li>feeling hot or cold</li><li>abnormal liver test results</li></ul><p><strong>&nbsp;</strong></p><p><strong>Rare </strong>(may affect up to 1 in 1,000 people)</p><ul><li>low levels of salt in the blood</li><li>reduction in blood platelets, which increases risk of bleeding or bruising</li><li>reduction in white blood cell count</li><li>untypical wild behavior</li><li>hallucinations</li><li>agitation</li><li>panic attacks</li><li>confusion</li><li>stuttering</li><li>aggression</li><li>fits</li><li>vasculitis (inflammation of a blood vessel)</li><li>rapid swelling of the tissues around the neck, face, mouth and/or throat</li><li>pain in the tube that takes food or water to your stomach</li><li>hepatitis</li><li>lung problems</li><li>sensitivity to sunlight</li><li>muscle pain</li><li>problems urinating</li><li>producing breast milk</li></ul><p><strong>Not Known</strong></p><ul><li>Heavy vaginal bleeding shortly after birth (postpartum haemorrhage), see Pregnancy in section 2 for more information</li></ul><p><strong>Bone fractures </strong>- an increased risk of bone fractures has been observed in patients taking this type of medicines.</p><p>Most of these side effects are likely to disappear with continued treatment.</p><p><em>In children and adolescents (8-18 years) </em>&ndash; In addition to the possible side effects listed above, FLOZAK may slow growth or possibly delay sexual maturity. Suicide-related behaviors (suicide attempt and suicidal thoughts), hostility, mania and nose bleeds were also commonly reported in children.</p><p><strong>If you get any side-effects, talk to your doctor, pharmacist or nurse. This includes any possible side effects not listed in this leaflet.</strong></p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>- Keep out of the sight and reach of children.</p><p>- Store below 30&deg;C.</p><p>- Keep in the original pack to protect from light and moisture.</p><p>- In use instructions: use during one month after first opening.</p><p>- Do not use this medicine after the expiry date which is stated on the carton.</p><p>- Do not throw away any medicines via wastewater or household waste. Ask your pharmacist how to throw away medicines you no longer use. These measures will help to protect the environment.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The <strong>active substance </strong>is Fluoxetine hydrochloride. Each capsule contains Fluoxetine Hydrochloride BP equivalent to Fluoxetine 20 mg.</p><p>Other ingredients: Maize Starch, Purified Talc, Colloidal Anhydrous Silica, Magnesium Stearate and Capsule Shells (Size 2).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Capsules having slightly yellow coloured body and light green coloured head with printing RP 12  in black ink on head containing white to off white powder.
Pack size:
Each pack of FLOZAK 20 mg capsules contains 30 capsules in white plastic container with white plastic cap.
Hospital packs of FLOZAK 20 mg.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)</p><p>P.O.Box 442, Riyadh 11411</p><p>Fax: +966 11 265 0505</p><p>Email: contact@riyadhpharma.com</p><p><em>For any information about this medicinal product, please contact the local representative of marketing authorization holder:</em></p><p>Saudi Arabia</p><p>Marketing department</p><p>Riyadh</p><p>Tel: +966 11 265 0111</p><p>Email: marketing@riyadhpharma.com</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                11/2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>يحتوي فلوزاك 20 ملجم على المادة الفعالة فلوكستين وهي واحدة من مجموعة الأدوية المضادة للاكتئاب تسمى مثبطات إعادة امتصاص السيروتونين.</p><p><strong>يستخدم هذا الدواء لعلاج الحالات التالية</strong><strong>:</strong></p><p><strong>الكبار</strong>:</p><ul><li>الاضطراب الأكتئابي الحاد.</li><li>اضطراب الوسواس القهري</li><li>مرض الشره العصبي: يستخدم فلوزاك جنبا إلى جنب مع العلاج النفسي للحد من الإفراط في الأكل.</li></ul><p><strong>الأطفال والمراهقين من 8 سنوات وما فوق</strong><strong>:</strong></p><ul><li>الاضطراب الأكتئابي الحاد من متوسط الي شديد الحدة، إذا لم يستجب الاكتئاب للعلاج النفسي بعد 4-6 جلسات. ينبغي أن يقدم فلوزاك للطفل أو الشاب المصاب بالاضطراب الأكتئابي الحاد من متوسط الي شديد الحدة فقط بالإضافة الي العلاج النفسي.</li></ul><p><strong>كيف يعمل</strong><strong> </strong><strong>فلوزاك</strong><br />كل شخص لديه مادة تسمى السيروتونين في الدماغ. الاشخاص المصابون بالاكتئاب أو لديك الوسواس القهري أو مرض الشره العصبي، لديهم مستويات منخفضة من السيروتونين عن غيرهم. &nbsp;ليس مفهوم بشكل كامل كيف يعمل فلوزاك ومثبطات إعادة امتصاص السيروتونين الأخرى ولكنها قد تساعد من خلال زيادة مستوى السيروتونين في الدماغ.<br />علاج هذه الحالات مهم حتى يساعدك على التحسن. لأنه إذا لم يتم علاجها، حالتك قد لا تتحسن ويمكن أن تتدهور أكثر وأكثر صعوبة للعلاج.<br />قد تحتاج ان تعالج لبضعة أسابيع أو أشهر لضمان أن تتخلص من الأعراض.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p dir="RTL"><strong>ثمانيه أشياء هامة تحتاج إلى معرفتها</strong><strong> عن</strong><strong> </strong><strong>فلوزاك</strong></p><ul dir="rtl"><li><strong>فلوزاك </strong><strong>يستخدم لعلاج الاكتئاب واضطرابات القلق</strong><strong>.</strong></li></ul><p dir="RTL">مثل جميع الأدوية يمكن أن يكون لها آثار غير مرغوب فيها. ولذلك فمن المهم أن تقوم انت وطبيبك بتقييم فوائد العلاج مقابل الآثار غير المرغوب فيها المحتملة، قبل بدء العلاج.</p><ul dir="rtl"><li><strong>فلوزاك </strong><strong>ليس للاستخدام مع الأطفال والمراهقين تحت 18</strong>, انظر القسم 2.&quot; <em>الأطفال والمراهقين الذين تتراوح أعمارهم بين</em>&nbsp;<em>8-18عاما&quot;</em><em>.</em></li><li><strong>فلوزاك </strong><strong>لا يعمل على الفور</strong>، بعض الأشخاص الذين يتناولون مضادات الاكتئاب يشعرون بتدهور حالتهم قبل الشعور بالتحسن. يجب على طبيبك أن يطلب منك مراجعته بعد أسبوعين من بدء العلاج. أخبر طبيبك إذا لم تكن قد بدأت بالشعور بالتحسن. انظر القسم 3، &quot; <em>كيفية تناول كبسولات فلوزاك</em><em>&quot;</em>.</li><li><strong>بعض الناس المصابين بالاكتئاب أو القلق يفكروا بإيذاء أو قتل أنفسهم.</strong> إذا بدأت بالشعور بالتدهور، أو التفكير في إيذاء أو قتل نفسك.راجع طبيبك أو اذهب إلى المستشفى على الفور. انظر القسم 2.</li><li><strong>لا تتوقف عن تناول</strong><strong> </strong><strong>فلوزاك </strong><strong>دون التحدث مع طبيبك</strong>. إذا توقفت عن تناول فلوزاك فجأة أو فوت جرعة، قد يحدث لك آثار انسحاب. انظر القسم 3 لمزيد من المعلومات.</li><li><strong>إذا كنت تشعر بفرط الحركة وتشعر بانة لا يمكنك الجلوس أو الوقوف دون حراك،</strong> أخبر طبيبك. زيادة جرعة فلوزاك &nbsp;قد تجعل هذه الأعراض اسوأ. انظر القسم 4،&quot; <em>الآثار الجانبية المحتملة&quot;</em>.</li><li><strong>تناول بعض الأدوية الأخرى مع</strong><strong> </strong><strong>فلوزاك قد </strong><strong>يسبب مشاكل</strong>. قد تحتاج إلى التحدث مع طبيبك. &nbsp;انظر القسم 2،&quot; <em>تناول أدوية أخرى&quot;</em>.</li><li><strong>إذا كنتي حاملا أو تخططين للحمل</strong>، تحدثي الى الطبيب. انظري القسم 2،&quot; <em>الحمل، الرضاعة الطبيعية والخصوبة&quot;</em>.</li></ul><p><strong>لا تتناول</strong><strong> </strong><strong>فلوزاك</strong><strong> </strong><strong>إذا كان لديك</strong><strong>:</strong></p><ul><li dir="rtl">حساسية لفلوكستين أو أي من المكونات الأخرى من هذا الدواء (المدرجة في المادة 6). إذا حدث لك طفح جلدي أو تفاعلات الحساسية اخرى (مثل الحكة وتورم الشفتين أو الوجه أو ضيق في التنفس)، توقف عن تناول كبسولات على الفور واتصل بطبيبك على الفور.</li><li dir="rtl">تناول أدوية أخرى تعرف باسم مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية، حيث ان تفاعلات خطيرة أو حتى مميتة يمكن أن تحدث (مثل: إيبرونيازيد المستخدم لعلاج الاكتئاب).</li></ul><p>يجب أن تبدأ العلاج مع فلوزاك فقط بعد 2 أسابيع على الأقل من ايقاف أي من مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية.</p><p><strong>لا تتناول</strong> أي من مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية اللارجعية وغير الانتقائية لمدة 5 أسابيع على الأقل بعد التوقف عن تناول فلوزاك. إذا تم وصف فلوزاك لفترة طويلة و/ أو بجرعة عالية، قد تحتاج إلى فترة أطول يجب ان تعتبر من قبل الطبيب.</p><ul><li>كنت تتناول الميتوبرولول (لعلاج قصور القلب) حيث أنه يوجد خطر متزايد من ان تصبح دقات قلبك بطيئة جدا.</li></ul><p><strong>التحذيرات والاحتياطات</strong><br />تحدث مع طبيبك أو الصيدلاني قبل تناول فلوزاك إذا كان أي من التالي ينطبق عليك:</p><ul><li>مشاكل في القلب.</li><li>ظهور الحمى، وتصلب العضلات أو تشنجها، والتغييرات في الحالة العقلية الخاصة بك مثل الارتباك، والتهيج والإثارة الشديدة؛ قد تعاني مما يسمى ب &quot;متلازمة السيروتونين&quot; أو &quot;المتلازمة الخبيثة للدواء المضاد للذهان&quot; على الرغم من أن هذه المتلازمة تحدث نادرا فإنه قد تكون مهددة للحياة؛ اتصل بطبيبك على الفور، حيث انه قد تحتاج لإيقاف تناول فلوزاك.</li><li>الاصابة بالهوس حاليا أو في الماضي؛ إذا كان لديك نوبة هوس، اتصل بطبيبك على الفور حيث انه قد تحتاج لإيقاف تناول فلوزاك.</li><li>إذا كنت تعاني في الماضي من اضطرابات النزيف أو ظهور كدمات أو نزيف غير عادي.أو إذا كنت حاملاً (انظر &quot;الحمل&quot;).</li><li>العلاج الحالي بالأدوية التي تقلل سيولة الدم (انظر &quot;الأدوية الأخرى وفلوزاك)؛</li><li>الصرع أو النوبات. إذا كان لديك نوبة (النوبات) أو تشهد زيادة في وتيرة التشنجات، اتصل بطبيبك على الفور حيث انه قد تحتاج لإيقاف تناول فلوزاك</li><li>العلاج الحالي بالصدمات الكهربائية (علاج التشنجات بالكهرباء)؛</li><li>العلاج الحالي بعقار تاموكسيفين (يستخدم لعلاج سرطان الثدي) (انظر &quot;الأدوية أخرى وفلوزاك)؛</li><li>إذا كنت تشعر بفرط الحركة وتشعر بانة لا يمكنك الجلوس أو الوقوف دون حراك، زيادة جرعة فلوزاك قد تجعل هذه الأعراض اسوأ.</li><li>السكري (طبيبك قد يحتاج إلى تعديل الجرعة الأنسولين أو غيره من الادوية المضادة لمرض السكر)؛</li><li>مشاكل في الكبد (طبيبك قد يحتاج إلى تعديل الجرعة)؛</li><li>معدل ضربات القلب منخفضة في حال الراحة و / أو إذا كنت تعرف أنك قد تعاني من نضوب الاملاح نتيجة للإسهال الشديد والقيء لفترات طويلة أو تستخدم مدرات البول (أقراص الماء)؛</li><li>العلاج الحالي بمدرات البول (أقراص الماء)، وخاصة إذا كنت من كبار السن.</li><li>المياه الزرقاء (ارتفاع الضغط في العين)؛</li></ul><p><strong>أفكار الانتحار وتفاقم الاكتئاب أو اضطراب القلق</strong></p><p>إذا كنت مكتئبا و / أو لديك اضطرابات القلق يمكن أن يكون في بعض الأحيان لديك أفكار بإيذاء أو قتل نفسك. هذه الافكار يمكن أن تزداد عند بداية العلاج بمضادات الاكتئاب لأول مرة، لأن هذه الأدوية كلها تستغرق وقتا طويلا للعمل، في العادة حوالي أسبوعين لكن في بعض الأحيان فترة أطول.<br />قد تكون أكثر عرضة للتفكير بهذه الطريقة:</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; إذا كان لديك أفكار سابقة حول قتل أو إيذاء نفسك.</p><p>-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; &nbsp;إذا كنت من الشباب البالغين. فقد أظهرت المعلومات المستقاة من التجارب السريرية زيادة خطر السلوك الانتحاري لدى البالغين الذين تقل أعمارهم عن 25 عاما الذين يعانون من حالات نفسية والذين عولجوا بمضادات للاكتئاب.</p><p><strong>إذا كان لديك أفكار إيذاء أو قتل نفسك في أي وقت، اتصل بطبيبك أو اذهب إلى المستشفى على الفور</strong><strong>.</strong><br /><strong>قد تجد أنه من المفيد إخبار </strong>أحد<strong> </strong>الاقارب او صديق قريب الذي كنت مكتئبا أو لديها اضطرابات القلق، وأطلب منهم أن قراءة هذه النشرة. قد تطلب منهم ان يخبروك إذا كانوا يعتقدون ان الاكتئاب أو القلق لديك يزداد سوءا، أو إذا كانوا يقلقون بشأن تغيرات في السلوك الخاص بك.</p><p><strong>الأطفال والمراهقين الذين تتراوح أعمارهم بين 8-18 سنة</strong><strong>:</strong><br />المرضى الذين تقل أعمارهم عن 18 سنة لديهم خطر متزايد من الآثار الجانبية مثل محاولة الانتحار، وأفكار انتحارية والعداء (في الغالب الغضب الشديد، وسلوك المعارضة) عندما يتناولون هذه الفئة من الأدوية. فلوزاك يجب أن يستخدم فقط في الأطفال والمراهقين الذين تتراوح أعمارهم بين 8-18 سنوات لعلاج نوبات الاضطراب الأكتئابي الحاد&nbsp; من متوسط الي شديد (بالاشتراك مع العلاج النفسي)، وأنه لا ينبغي أن يستخدم لعلاج حالات أخرى.<br />بالإضافة إلى ذلك، يوجد فقط معلومات محدودة بشأن السلامة على المدى الطويل لاستخدام فلوزاك على النمو والبلوغ، والتطور العقلي و العاطفي والسلوكي و النفسي لهذه الفئة العمرية على الرغم من هذا، وإذا كنت مريضا تحت 18 عاما، قد يصف الطبيب فلوزاك لعلاج نوبات الاضطراب الأكتئابي الحاد&nbsp; من متوسط الي شديد ، إلى جانب العلاج النفسي، لأنه / أنها قرر أن هذا العلاج هو في مصلحتك. إذا وصف طبيبك فلوزاك لمريض تحت18 سنة، وترغب في مناقشة هذا الموضوع، يرجى الرجوع إلى الطبيب. يجب إبلاغ الطبيب إذا كان أي من الأعراض المذكورة أعلاه تحدث أو تزداد سوءا عند المرضى الذين تقل أعمارهم عن 18 يتناولون فلوزاك.<br />فلوزاك لا ينبغي أن يستخدم في علاج الأطفال الذين تقل أعمارهم عن 8 سنوات.<br />&nbsp;</p><p><strong>الأدوية الأخرى و</strong><strong>فلوزاك </strong><br />أخبر طبيبك أو الصيدلي إذا كنت تتناول، او تناولت مؤخرا أو قد تتناول أي أدوية أخرى.<br /><strong>لا تتناول</strong><strong> </strong><strong>فلوزاك </strong><strong>مع</strong><strong>:</strong></p><ul><li>بعض مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية والتي تستخدم لعلاج الاكتئاب. يجب ألا تستخدم مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية مع فلوزاك حيث ان ردود فعل خطيرة أو حتى مميتة يمكن أن يحدث (متلازمة السيروتونين) (انظر القسم &quot; لا تتناول فلوزاك إذا كان لديك&quot;). يجب أن تبدأ العلاج مع فلوزاك على الاقل بعد 2 أسابيع على الأقل من وقف مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية، (على سبيل المثال ترانيلسيبرومين). لا تتناول أي من مثبطات أوكسيديز<strong> </strong>الأمينات الأحادية ألا رجعية وغير الانتقائية لمدة 5 أسابيع على الأقل بعد التوقف عن تناول فلوزاك. إذا تم وصف فلوزاك لفترة طويلة و / أو بجرعة اعلي، قد تحتاج إلى فترة أطول من 5 اسابيع يجب ان تعتبر من قبل الطبيب.</li><li>الميتوبرولول عندما يستخدم لفشل القلب؛ هناك خطر متزايد من ان ضربات قلبك تصبح بطيئة جدا.</li></ul><p><strong>فلوزاك </strong><strong>قد تؤثر على طريقة عمل الأدوية التالية (التفاعلات</strong><strong>)</strong></p><ul><li><strong>تاموكسيفين</strong> (يستخدم لعلاج سرطان الثدي). لأن فلوزاك يمكن أن يغير مستويات هذا الدواء في الدم، مما قد يؤدى إلى إمكانية تقليل تأثير عقار تاموكسيفين، فإن طبيبك قد يحتاج إلى النظر في وصف علاج مضاد للاكتئاب مختلف.</li><li><strong>مثبطات أوكسيديز الأمينات الأحادية - ا </strong>&nbsp;بما في ذلك موكلوبميد، لينزوليد (مضاد حيوي) وكلوريد الميثثيونونينيم (وتسمى أيضا أزرق الميثيلين) لوجود خطر ردود فعل خطيرة أو حتى مميتة (وتسمى متلازمة السيروتونين). &nbsp;العلاج مع فلوكستين يمكن أن يبدأ اليوم التالي بعد وقف العلاج بمثبطات أوكسيديز<strong> </strong>الأمينات الأحادية الرجعية ولكن قد يرغب الطبيب في مراقبتك بعناية واستخدام جرعة أقل من مثبطات أوكسيديز الأمينات الأحادية -<strong> ا</strong>.</li><li><strong>ميكويتازين</strong> (للحساسية)؛ لأن تناول هذا الدواء مع فلوزاك قد يزيد من مخاطر التغير في النشاط الكهربائي للقلب.</li><li><strong>الفينيتوين</strong> (للصرع)؛ لأن فلوزاك قد تؤثر على مستويات هذا الدواء في الدم، قد يحتاج الطبيب إلى بدأ العلاج بالفينيتوين بعناية أكثر وإجراء فحوص عندما يعطى مع فلوزاك.</li><li><strong>الليثيوم، وسيليجيلين، ونبتة سانت جون، وترامادول </strong>(مسكن)، <strong>أدوية التريبتان</strong> (الصداع النصفي) <strong>والتربتوفان</strong>. هناك خطر متزايد من متلازمة السيروتونين خفيفة عندما تتناول هذه العقاقير مع فلوزاك. &nbsp;سوف يقوم طبيبك بفحوصات طبية بوتيرة أكثر.</li><li>الأدوية التي يمكن ان تؤثر على ضربات القلب، على سبيل المثال <strong>مضادات عدم انتظام ضربات القلب من الفئة 1أ و 3</strong>، <strong>مضادات الذهان </strong>(مثل مشتقات الفينوثيازين، بيموزيد، هالوبيريدول)، <strong>مضادات الاكتئاب ثلاثية الحلقات</strong>، وبعض <strong>الادوية المضادة للجراثيم</strong> (على سبيل المثال سبرافلوكساسين، موكسيفلوكساسين، الاريثروميسين IV، بنتاميدين)، <strong>وعلاج المضاد للملاريا</strong> و بخاصة هالوفانترين أو <strong>بعض مضادات الحساسية</strong> (استيميزول, ميزولاستين). لان تناول واحد أو أكثر من هذه الأدوية مع فلوزاك قد يزيد من مخاطر التغيرات في النشاط الكهربائي للقلب.</li><li><strong>مضادات التخثر</strong> (مثل الوارفارين)، المسكنات مثل (ابيبروفين، ديكلوفيناك)، <strong>والأسبرين</strong> وغيرها من <strong>الأدوية التي يمكن أن تميع الدم</strong> (بما في ذلك كلوزابين، يستخدم لعلاج بعض الاضطرابات النفسية). فلوزاك قد يغير من تأثير هذه الأدوية على الدم. إذا بدأ العلاج مع فلوزاك أو توقف عندما كنت تتناول الوارفارين، سوف يحتاج طبيبك إلى إجراء بعض الاختبارات، وضبط جرعتك والتحقق من حالتك في كثير من الأحيان.</li><li>سيبروهيبتادين (للحساسية)؛ لأنه قد يقلل من تأثير فلوزاك.</li><li>الأدوية التي تخفض مستويات الصوديوم في الدم (بما في ذلك الادوية التي تسبب زيادة في التبول، ديزموبريسين، كاربامازيبين و اوكسكاربامازيبين)، لأن هذه الأدوية قد تزيد من خطر انخفاض مستويات الصوديوم في الدم عندما تتناول مع فلوزاك.</li><li><strong>مضادات الاكتئاب</strong> مثل مضادات الاكتئاب ثلاثية الحلقات، وغيرها من مثبطات امتصاص السيروتونين الانتقائية أو بوبروبيون، <strong>ميفلوكين</strong> أو <strong>الكلوروكين</strong> (التي تستخدم لعلاج الملاريا)<strong> وترامادول </strong>(مسكن لعلاج الام الشديد)، أو <strong>مضادات الذهان</strong> مثل الفينوثيازين أو بيوتيل الاورفينون. لأن فلوزاك قد يزيد من خطر النوبات عندما يتناول مع هذه الأدوية.</li><li><strong>فليسيانيد</strong>، <strong>بروبافينون</strong>، <strong>نيبيفلول</strong> أو <strong>انسياني</strong> (لمشاكل القلب)، كاربامازيبين (للصرع)، اتومكيسيتين أو مضادات الاكتئاب ثلاثية الحلقات (على سبيل المثال إيميبرامين، ديسيبرامين وأميتريبتيلين) أو ريسبيريدون (للفصام)؛ لأن فلوزاك قد يغيير مستويات هذه الأدوية في الدم)، طبيبك قد يحتاج إلى خفض جرعة هذة الادوية عندما تتناول مع فلوزاك.</li></ul><p><strong>فلوزاك </strong><strong>مع الطعام والشراب والكحول</strong></p><ul><li>يمكنك أن تتناول فلوزاك مع او بدون الطعام، أي كنت تفضل.</li><li>يجب تجنب الكحول أثناء تناول هذا الدواء.</li></ul><p><strong>الحمل، الرضاعة الطبيعية والخصوبة</strong><br />إذا كنتي حاملا أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك قد تكونين حاملا أو تخططي لإنجاب طفل، احصلي على مشورة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p><strong>الحمل</strong><br />تحدثي مع طبيبك في أقرب وقت ممكن إذا كنتي حاملا أو تقومين بالرضاعة الطبيعية، أو تعتقدين أنك قد تكونين حاملا أو تخططي لإنجاب طفل، احصلي على مشورة طبيبك أو الصيدلي قبل تناول هذا الدواء.</p><p dir="RTL">إذا تناولتي فلوزاك بالقرب من نهاية الحمل ، فقد يكون هناك خطر متزايد من حدوث نزيف مهبلي حاد بعد الولادة بفترة وجيزة ، خاصة إذا كان لديكِ تاريخ من اضطرابات النزيف. يجب أن يدرك طبيبك أو ممرضة التوليد أنكِ تتناولين فلوزاك حتى يتمكنوا من تقديم النصح لكِ.</p><p>بالنسبة للأطفال الذين تناولت امهاتهم فلوكستين خلال الأشهر القليلة الأولى من الحمل، يوجد هناك بعض التقارير تشير إلى زيادة خطر العيوب الخلقية التي تصيب القلب. &nbsp;فانة على وجه العموم، يولد حوالي 1 في 100 طفل مع عيب في القلب. وهذه النسبة تزداد إلى حوالي 2 في 100 طفل في الأمهات الذين تناولوا فلوكستين. قد تقررين أنتى وطبيبك أنه من الأفضل لك أن توقفي تدريجيا تناول فلوزاك في حال كنتي حاملا. ومع ذلك، وهذا يتوقف على ظروفك الخاصة، قد يقترح الطبيب أنه من الأفضل لك أن تبقى على تناول فلوزاك.<br />عندما يتناول خلال فترة الحمل، وخصوصا في آخر 3 أشهر من الحمل، الأدوية مثل فلوكستين قد تزيد من خطر حدوث حالة خطيرة في الأطفال، وهو ما يسمى بارتفاع ضغط الدم الرئوي المستمر لحديثي الولادة، مما يجعل الطفل يتنفس بشكل أسرع ويميل لونة للأزرق. عادة ما تبدأ هذه الأعراض خلال ال 24 ساعة الأولى بعد ولادة الطفل. إذا كان هذا يحدث لطفلك يجب عليك الاتصال قابلتك و / أو طبيبك على الفور.<br />ينبغي توخي الحذر عند الاستخدام خلال فترة الحمل، وخصوصا خلال المراحل الأخيرة من الحمل أو قبل الولادة حيث ان التأثيرات التالية تم ملاحظتها في الأطفال حديثي الولادة: التهيج، والارتعاش، وضعف العضلات، و البكاء المستمر، وصعوبة في الرضاعة أو في النوم.<br /><strong>الرضاعة الطبيعية</strong><br />يتم إفراز فلوكستين في حليب الثدي ويمكن أن يسبب في آثار جانبية عند الأطفال. يجب عليك فقط الإرضاع إذا كان ذلك ضروريا بشكل واضح. إذا استمرت الرضاعة الطبيعية، قد يصف الطبيب جرعة أقل من فلوكستين.<br /><strong>الخصوبة</strong><br />قد تبين ان فلوكستين يقلل من جودة الحيوانات المنوية في الدراسات الحيوانية. من الناحية النظرية، هذا قد يؤثر على الخصوبة، ولكن لم يلاحظ تأثير على خصوبة البشرية حتى الآن.</p><p><strong>القيادة واستخدام الآلات</strong><br />الأدوية النفسية مثل فلوزاك قد يؤثر على حكمك أو التنسيق. لا تقم بالقيادة أو استخدام الآلات حتى تعرف كيف يؤثر فلوزاك عليك.<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول دائما هذا الدواء تماما كتوجيهات طبيبك أو الصيدلي. استشر طبيبك أو الصيدلي إذا لم تكن متأكدا. لا تتناول كبسولات اكثر من ما يخبرك طبيبك.<br />ابتلع الكبسولات مع الماء. لا تمضغ الكبسولات.</p><p><strong>الكبار</strong></p><p>الجرعة الموصي بها هي:</p><ul><li><strong>الاكتئاب</strong>: الجرعة الموصي بها هي 1 كبسولة (20 ملجم) يوميا. قد يقوم الطبيب بتعديل الجرعة إذا لزم الامر فى غضون 3 الى 4 اسابيع من بدء العلاج، يمكن زيادة الجرعة تدريجيا، بحد اقصى 3 كبسولات (60 ملجم) يوميا. ينبغي زيادة الجرعة بعناية لضمان تناول أقل جرعة فعالة. قد لا تشعر بالتحسن على الفور عند بدء تناول علاج فلوزاك، والتحسن فى الاعراض قد لا يتم إلا بعد مرور اسابيع من بداية العلاج (في العادة اسبوعين أو اطول). مدة علاج مرضى الاكتئاب يجب ان تستمر لمدة لا تقل عن 6 أشهر</li><li><strong>الشره المرضي العصبي</strong>: الجرعة الموصي بها هي 3 كبسولات (60 ملجم) يوميا.</li><li><strong>الوسواس القهري</strong>: الجرعة الموصي بها هي 1 كبسولة (20 ملجم) يوميا. طبيبك سوف يستعرض ويعدل الجرعة إذا لزم الأمر بعد أسبوعين من العلاج. وإذا لزم الأمر ايضا، يمكن زيادة الجرعة تدريجيا إلى حد أقصى قدره 3 كبسولات (60 ملجم) يوميا. إذا لم تلاحظ أي تحسن في غضون 10 أسابيع، طبيبك سوف يعيد النظر في علاجك.</li><li><strong>الأطفال والمراهقين الذين تتراوح أعمارهم بين 8 سنوات و18 سنة يعانون من الاكتئاب</strong><strong>:</strong> يجب أن تبدأ العلاج تحت اشراف طبيب متخصص. جرعة البداية هي 10 ملجم يوميا. بعد اسبوع الى اسبوعين، قد يقوم طبيبك بزيادة الجرعة إلى 20 ملجم يوميا. ينبغي زيادة الجرعة بعناية لضمان أنك تتناول أقل جرعة فعالة. &nbsp;للأطفال الذين تكون اوزانهم اقل قد يحتاجون لجرعة أقل. إذا كان هناك استجابة مرضية للعلاج، فسيقوم طبيبك بمراجعة الحاجة الى مواصلة العلاج بعد 6 أشهر. إذا لم تتحسن خلال 9 أسابيع، فسيقوم طبيبك بإعادة تقييم العلاج.</li><li><strong>كبار السن</strong>: سيقوم طبيبك بزيادة الجرعة مع المزيد من الحذر و ينبغي أن لا تتجاوز الجرعة اليومية كبسولتين (40 ملجم), الجرعة القصوى هي 3 كبسولات (60 ملجم) يوميا.</li><li><strong>قصور الكبد</strong><strong>:</strong> إذا كان لديك مشكلة في الكبد أو تستخدم أدوية أخرى والتي قد تؤثر على فلوزاك، فقد يقرر طبيبك أن يصف لك جرعة أقل أو قد يطلب منك ان تتناول فلوزاك<strong> </strong>يوم بعد يوم.</li></ul><p><strong>إذا تناولت أكثر مما يجب من</strong><strong> فلوزاك</strong></p><ul><li>إذا تناولت أكثر مما يجب من فلوزاك يجب عليك التحدث إلى الطبيب أو الذهاب إلى المستشفى على الفور.</li><li>اصطحب معك علبة فلوزاك إذا امكن.</li></ul><p>أعراض الجرعة الزائدة تشمل: الغثيان، والتقيؤ، والتشنجات، ومشاكل في القلب (مثل عدم انتظام ضربات القلب والسكتة القلبية)، مشاكل في الرئة وتغير في الحالة العقلية التي تتراوح بين التهيج إلى الغيبوبة.</p><p><strong>إذا نسيت تناول</strong><strong> فلوزاك</strong></p><ul><li>إذا نسيت تناول جرعة، تغاضى عن الجرعة المنسية. ثم تناول الجرعة التالية كالمعتاد. لا تتناول جرعة مضاعفة للتعويض عن الجرعة المنسية.</li><li>تناولك للدواء في نفس التوقيت كل يوم قد يساعدك على تذكر تناول الدواء بانتظام.</li></ul><p><strong>إذا توقفت عن تناول</strong><strong> </strong><strong>فلوزاك</strong></p><ul><li>لا تتوقف عن تناول فلوزاك<strong> </strong>دون استشارة الطبيب أولا، حتى عندما تبدأ بالشعور بشكل أفضل. من المهم أن تحافظ على تناول الدواء الخاص بك.</li><li>تأكد من أن لديك كمية كافية من كبسولات.</li></ul><p>قد تلاحظ التأثيرات التالية (آثار الانسحاب) عندما تتوقف عن تناول فلوزاك: الدوار. مشاعر وخز مثل الدبابيس والإبر. اضطرابات النوم (أحلام اليقظة والكوابيس، وعدم القدرة على النوم)؛ شعور بعدم الراحة والهيجان. تعب غير طبيعي أو ضعف. الشعور بالقلق. الغثيان / القيء (الشعور بالغثيان أو الشعور بالمرض)؛ الرعشة (الاهتزاز)؛ الصداع.<br />معظم الناس يجدون أن أي أعراض تظهر عند وقف فلوزاك<strong> </strong>تكون خفيفة وتختفي في غضون أسابيع قليلة. فى حالة ظهور اعراض عند التوقف عن العلاج، اتصل بطبيبك.<br />عند التوقف عن تناول فلوزاك<strong>،</strong> فأن طبيبك سوف يساعدك على خفض الجرعة ببطء على مدى أسبوع أو أسبوعين - وهذا ينبغى أن يساعد على التقليل من فرصة ظهور آثار الانسحاب.<br />إذا كان لديك أي أسئلة أخرى عن استخدام هذا الدواء، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل جميع الأدوية، يمكن لهذا الدواء أن يسبب آثارا جانبية، وعلى الرغم من أن ليس كل شخص تحدث له.</p><ul><li>إذا كان لديك أفكار بإيذاء أو قتل نفسك في أي وقت، <strong>اتصل بطبيبك أو اذهب إلى المستشفى على الفور</strong> (أنظر القسم 2).</li><li>إذا حصلت على طفح جلدي أو حساسية مثل الحكة وتورم الشفاه / اللسان أو الصفير / ضيق في التنفس، <strong>توقف عن تناول الكبسولات على الفور وأخبر طبيبك فورا</strong>.</li><li>إذا كنت تشعر بعدم الراحة ولا يمكنك الجلوس أو الوقوف دون حراك، قد يكون لديك فرط حركة. زيادة جرعة من فلوزاك قد يجعلك تشعر أسوأ. إذا كنت تشعر بذلك، <strong>اتصل بطبيبك</strong>.</li><li><strong>أ</strong><strong>خبر طبيبك فورا</strong> إذا كانت بشرتك تبدأ بالاحمرار أو كان لديك ردود فعل جلدية متنوعة أو بدأ ظهور البثور على بشرتك أو التقشر. هذا أمر نادر الحدوث جدا.</li><li>&nbsp;الأعراض الجانبية الأكثر شيوعا (الآثار الجانبية الشائعة جدا التي قد تؤثر على أكثر من 1 مستخدم في كل 10) هي والأرق، والصداع، والإسهال، والشعور بالمرض (الغثيان)، والتعب.</li></ul><p>بعض المرضى كان لديهم:</p><ul><li>مجموعة من الأعراض (تعرف باسم &quot;متلازمة السيروتونين&quot;) وتتضمن حمى غير مبررة مع تسارع التنفس أو تسارع معدل ضربات القلب، والتعرق، وتصلب العضلات أو الارتعاش، والارتباك، والتهيج الشديد أو النعاس (إلا نادرا)؛</li><li>الشعور بالضعف والنعاس أو الارتباك وخاصة في كبار السن والأشخاص الذين يتناولون مدرات البول (أقراص الماء)؛</li><li>الانتصاب لفترات طويلة ومؤلمة.</li><li>التهيج والإثارة الشديدة؛</li><li>مشاكل في القلب، مثل تسارع أو عدم انتظام ضربات القلب، والاغماء، والانهيار أو الدوخة عند الوقوف مما قد يشير إلى خلل في معدل ضربات القلب.</li></ul><p><strong>&nbsp;</strong></p><p><strong>إذا كان لديك أي من الآثار الجانبية المذكورة أعلاه، يجب عليك إخبار طبيبك فورا</strong><strong>.</strong><br />الآثار الجانبية التالية تم الابلاغ عنها في المرضى الذين يتناولون فلوزاك</p><p>&nbsp;</p><p>&nbsp;<strong>شائعة</strong><strong> (تلاحظ في 1 الي 10 من بين 100 مريض)</strong></p><ul><li>عدم الشعور بالجوع، وفقدان الوزن</li><li>العصبية والقلق</li><li>الأرق، ضعف التركيز</li><li>الشعور بالتوتر</li><li>انخفاض الدافع الجنسي أو المشاكل الجنسية (بما في ذلك صعوبة في الحفاظ على الانتصاب لممارسة النشاط الجنسي)</li><li>مشاكل في النوم، الأحلام غير العادية، التعب أو النعاس</li><li>الدوخة</li><li>تغير في الذوق</li><li>حركات الهز التي لا يمكن السيطرة عليها</li><li>عدم وضوح الرؤية</li><li>الأحاسيس بسرعة وعدم انتظام ضربات القلب</li><li>التوهج</li><li>التثاؤب</li><li>عسر الهضم، القيء</li><li>جاف الفم</li><li>طفح جلدي، شرى، حكة</li><li>زيادة التعرق</li><li>آلام المفاصل</li><li>كثرة عدد مرات التبول</li><li>نزيف مهبلي غير معروف السبب.</li><li>الشعور برعشة أو قشعريرة</li></ul><p><strong>غير </strong><strong>شائعة (تلاحظ في 1 من بين 100 مريض)</strong></p><ul><li>عدم الشعور بذاتك</li><li>التفكير الغريب</li><li>الانتشاء غير عادي</li><li>مشاكل النشوة الجنسية</li><li>التفكير في الانتحار أو إيذاء نفسك</li><li>طحن الأسنان</li><li>ارتعاش العضلات، والحركات اللاإرادية أو مشاكل في التوازن أو التنسيق</li><li>ضعف الذاكرة</li><li>اتساع حدقة العين</li><li>طنين في الأذن</li><li>ضغط الدم المنخفض</li><li>ضيق النفس</li><li>نزيف الأنف</li><li>صعوبة البلع</li><li>تساقط الشعر</li><li>زيادة حدوث كدمات</li><li>كدمات أو نزف غير مفسر</li><li>عرق بارد</li><li>صعوبة في التبول</li><li>الشعور بالسخونة أو بالبرد</li><li>نتائج غير طبيعية لاختبارات الكبد</li></ul><p><strong>نادرة</strong> <strong>(تلاحظ في 1 من بين 1000 مريض)</strong></p><ul><li>انخفاض نسبة الملح في الدم</li><li>انخفاض في الصفائح الدموية، مما يزيد من خطر حدوث نزيف أو كدمات</li><li>انخفاض في عدد خلايا الدم البيضاء</li><li>السلوك الوحشي غير النموذجي</li><li>الهلوسة</li><li>الهياج</li><li>نوبات الهلع</li><li>الارتباك</li><li>التأتأة</li><li>العدوان</li><li>نوبات</li><li>التهاب الأوعية الدموية</li><li>تورم السريع للأنسجة حول الرقبة والوجه والفم و / أو الحلق</li><li>ألم في الأنبوب الذي يأخذ الطعام أو الماء إلى المعدة</li><li>التهاب الكبد</li><li>مشاكل في الرئة</li><li>حساسية لأشعة الشمس</li><li>آلام في العضلات</li><li>مشاكل التبول</li><li>إنتاج حليب الثدي</li></ul><p dir="RTL"><strong>غير معروف</strong></p><p dir="RTL"><strong>&middot;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; </strong>نزيف مهبلي غزير بعد الولادة بفترة قصيرة (نزيف ما بعد الولادة) ، انظر الحمل في القسم 2 لمزيد من المعلومات.</p><p><strong>كسور العظام</strong> &ndash; تم ملاحظة زيادة خطر كسور العظام عند المرضى الذين يتناولون هذا النوع من الأدوية.<br />معظم هذه الآثار الجانبية من المحتمل أن تختفي مع استمرار العلاج.<br />في الأطفال والمراهقين (من سن 8 الي 18 سنوات) - بالإضافة إلى الآثار الجانبية المحتملة المذكورة أعلاه، قد يؤدى فلوزاك لبطء النمو أو ربما تأخير النضج الجنسي. &nbsp;السلوكيات المرتبطة بالميل للانتحار (محاولة الانتحار وأفكار انتحارية)، والعداء، والهوس ونزيف الأنف عند الأطفال تم الابلاغ عن حدوثها في الاطفال.</p><p><strong>تحدث مع طبيبك، الصيدلي أو&nbsp;الممرض إذا لاحظت أي من الأثار الجانبية،&nbsp;وهذا يشمل الأثار الجانبية المحتملة&nbsp;الغير مدرجة في هذه النشرة.</strong></p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>- يحفظ بعيدا عن مرأى ومتناول الأطفال.</p><p>- يحفظ في درجة حرارة أقل من 30 درجة مئوية.</p><p>- يحفظ في العبوة الاصلية للحماية من الضوء والرطوية.</p><p>- الاستخدام فـيما بعد الفتح: يستخدم خلال شهر واحد من أول فتح للعبوة.</p><p>- يجب عدم استعمال فلوزاك<strong> </strong>بعد تاريخ انتهاء الصلاحية المذكور على العبوة.</p><p>- التخلص من الأدوية يجب ألا يكون عن طريق مياه الصرف الصحي أو النفايات المنزليه. اسأل الصيدلي عن كيفية التخلص من الأدوية التي لم تعد مطلوبه. هذة التدابير مساعده في حماية البيئة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>المادة الفعالة هي فلوكستين، تحتوي كل كبسولة على فلوكستين هيدروكلورايد (دستور الأدوية البريطاني) ما يعادل فلوكستين 20 ملجم.</p><p>المكونات الأخرى هي: نشا ذرة، تالك نقي، سيليكا لامائية غروية، مغنيسيوم ستياريت وغلاف كبسولة(حجم&nbsp;2</p><p>&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>فلوزاك عبارة عن كبسولات ذات جسم لونه أصفر فاتح ورأس لونه أخضر فاتح مطبوع عليهRP 12 باللون الأسود تحتوي على بودرة لونها أبيض الى أبيض داكن.</p><p>حجم العبوة:</p><p>كل عبوة من فلوزاك 20 ملجم تحتوي على 30 كبسولة في عبوات بلاستيكية بيضاء وغطاء بلاستيكي أبيض.</p><p>عبوات المستشفيات تحتوي على كبسولات فـلوزاك 20 ملجم.</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>شركة المنتجات الطبية والتجميلية المحدودة (الرياض فارما)</p><p>ص.ب. 442 الرياض 11411</p><p>فاكس: 966112650505+</p><p>البريد الإلكتروني: contact@riyadhpharma.com</p><p><em>لأية معلومات عن هذا المنتج الطبي، يرجى الاتصال على صاحب الترخيص والتسويق:</em></p><p>المملكة العربية السعودية</p><p>قسم التسويق</p><p>الرياض</p><p>تلفون: 966112650111+</p><p>البريد الإلكتروني: marketing@riyadhpharma.com</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            11/2020
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                FLOZAK Capsules
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Each capsule contains 20 mg of fluoxetine (as fluoxetine hydrochloride).
For the full list of excipients, see section 6.1
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Capsules having slightly yellow colored body and light green colored head with printing RP 12 in black ink on head containing white to off white powder.
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><strong>Adults:</strong><br />Major depressive episodes.<br />Obsessive-compulsive disorder.<br />Bulimia nervosa: FLOZAK is indicated as a complement of psychotherapy for the reduction of binge-eating and purging activity.</p><p><br /><strong>Children and adolescents aged 8 years and above:</strong><br />Moderate to severe major depressive episode, if depression is unresponsive to psychological therapy after 4-6 sessions. Antidepressant medication should be offered to a child or young person with moderate to severe depression only in combination with a concurrent psychological therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Posology<br />Adults</u></p><p><em>Major depressive episodes</em><br />Adults and the elderly: The recommended dose is 20mg daily. Dosage should be reviewed and adjusted if necessary, within 3 to 4 weeks of initiation of therapy and thereafter as judged clinically appropriate. Although there may be an increased potential for undesirable effects at higher doses, in some patients, with insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60mg (see section 5.1). Dosage adjustments should be made carefully on an individual patient basis, to maintain the patients at the lowest&nbsp; effective dose. Patients with depression should be treated for a sufficient period of at least 6 months to ensure that they are free from symptoms.<br /><em>Obsessive-compulsive disorder</em><br />Adults and the elderly: The recommended dose is 20mg daily. Although there may be an increased potential for undesirable effects at higher doses, in some patients, if after two weeks there is insufficient response to 20mg, the dose may be increased gradually up to a maximum of 60mg. If no improvement is observed within 10 weeks, treatment with fluoxetine should be reconsidered. If a good therapeutic response has been obtained, treatment can be continued at a dosage adjusted on an individual basis. While there are no systematic studies to answer the question of how long to continue fluoxetine treatment, OCD is a chronic condition and it is reasonable to consider continuation beyond 10 weeks in responding patients.<br />Dosage adjustments should be made carefully on an individual patient basis, to maintain the patient at thelowest effective dose. The need for treatment should be reassessed periodically. Some clinicians advocate concomitant behavioural psychotherapy for patients who have done well on pharmacotherapy. Long-term efficacy (more than 24 weeks) has not been demonstrated in OCD. Bulimia nervosa: Adults and the elderly: A dose of 60mg/day is recommended. Long-term efficacy (more than 3 months) has not been demonstrated in bulimia nervosa. All indications: The recommended dose may be increased or decreased. Doses above 80mg/day have not been systematically evaluated.<br /><em><u>Paediatric population - Children and adolescents aged 8 years and above (Moderate to severe major depressive episode)</u></em><br />Treatment should be initiated and monitored under specialist supervision. The starting dose is 10mg/day givenas 2.5ml of Fluoxetine oral solution. Dose adjustments should be made carefully, on an individual basis, to maintain the patient at the lowest effective dose. After one to two weeks, the dose may be increased to 20mg/day. Clinical trial experience with daily doses greater than 20mg is minimal. There is only limited data on treatment beyond 9 weeks. Lower-weight children: Due to higher plasma levels in lower-weight children, the therapeutic effect may be achieved with lower doses (see section 5.2). For paediatric patients who respond to treatment, the need for continued treatment after 6 months should be reviewed. If no clinical benefit is achieved within 9 weeks, treatment should be reconsidered.<br /><em><u>Elderly patients</u></em><br />Caution is recommended when increasing the dose, and the daily dose should generally not exceed 40mg. Maximum recommended dose is 60mg/day.<br /><em><u>Hepatic impairment</u></em><br />A lower or less frequent dose (e.g., 20mg every second day) should be considered in patients with hepatic impairment (see section 5.2), or in patients where concomitant medication has the potential for interaction with FLOZAK (see section 4.5).<br />Withdrawal symptoms seen on discontinuation of FLOZAK: Abrupt discontinuation should be avoided. When stopping treatment with FLOZAK the dose should be gradually reduced over a period of at least one to two weeks in order to reduce the risk of withdrawal reactions (see sections 4.4 and 4.8). If intolerable symptoms occur following a decrease in the dose or upon discontinuation of treatment, then resuming the previously prescribed dose may be considered. Subsequently, the physician may continue decreasing the dose, but at a more gradual rate.<br /><em><u>Method of administration</u></em><br />For oral administration.<br />Fluoxetine may be administered as a single or divided dose, during or between meals.<br />When dosing is stopped, active drug substances will persist in the body for weeks. This should be borne in mind when starting or stopping treatment.</p><p>The capsule and oral solution forms are bioequivalent.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Hypersensitivity to the active substance or to any of the excipients listed in section 6.1.
Fluoxetine is contra-indicated in combination with irreversible, non-selective monoamine oxidase inhibitors (e.g. iproniazid) (see sections 4.4 and 4.5).
Fluoxetine is contra-indicated in combination with metoprolol used in cardiac failure (see section 4.5).
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Paediatric population - Children and adolescents under 18 years of age</u></p><p>Suicide-related behaviours (suicide attempt and suicidal thoughts) and hostility (predominantly aggression,<br />oppositional behaviour and anger) were more frequently observed in clinical trials among children and adolescents treated with antidepressants compared to those treated with placebo. Fluoxetine should only be used in children and adolescents aged 8 to 18 years for the treatment of moderate to severe major depressive episodes and it should not be used in other indications. If, based on clinical need, a decision to treat is nevertheless taken, the patient should be carefully monitored for the appearance of suicidal symptoms. In addition, only limited evidence is available concerning long-term effect on safety in children and adolescents, including effects on growth, sexual maturation and cognitive, emotional and behavioural developments (see section 5.3). In a 19-week clinical trial, decreased height and weight gain was observed in children and adolescents treated with fluoxetine (see section 5.1). It has not been established whether there is an effect on achieving normal adult height. The possibility of a delay in puberty cannot be ruled out (see sections 5.3 and 4.8). Growth and pubertal development (height, weight, and TANNER staging) should therefore be monitored during and after treatment<br />with fluoxetine. If either is slowed, referral to a paediatrician should be considered. In paediatric trials, mania and hypomania were commonly reported (see section 4.8). Therefore, regular monitoring for the occurrence of mania/hypomania is recommended. Fluoxetine should be discontinued in any patient entering a manic phase.<br />It is important that the prescriber discusses carefully the risks and benefits of treatment with the child/young person and/or their parents.</p><p><u>Suicide/suicidal thoughts or clinical worsening</u></p><p>Depression is associated with an increased risk of suicidal thoughts, self-harm and suicide (suicide-related events). This risk persists until significant remission occurs. As improvement may not occur during the first few weeks or more of treatment, patients should be closely monitored until such improvement occurs. It is general clinical experience that the risk of suicide may increase in the early stages of recovery. Other psychiatric conditions for which FLOZAK is prescribed can also be associated with an increased risk of suicide-related events. In addition, these conditions may be co-morbid with major depressive disorder. The same precautions observed when treating patients with major depressive disorder should therefore be observed when treating patients with other psychiatric disorders. Patients with a history of suicide-related events, those exhibiting a significant degree of suicidal ideation prior to commencement of treatment are known to be at greater risk of suicidal thoughts or suicide attempts, and should receive careful monitoring during treatment. A meta-analysis of placebo-controlled clinical trials of antidepressants drugs in adult patients with psychiatric disorders showed an increased risk of suicidal behaviour with antidepressants compared to placebo in patients less than 25 years old. Close supervision of patients and in particular those at high risk should accompany drug therapy especially in early treatment and following dose changes. Patients (and caregivers of patients) should be alerted about the need to monitor for any clinical worsening, suicidal behaviour or thoughts and unusual changes in behaviour and to seek medical advice immediately if these symptoms present.</p><p><u>Cardiovascular Effects</u></p><p>Cases of QT interval prolongation and ventricular arrhythmia including torsades de pointes have been reported during the post-marketing period (see sections 4.5, 4.8 and 4.9). Fluoxetine should be used with caution in patients with conditions such as congenital long QT syndrome, a family history of QT prolongation or other clinical conditions that predispose to arrhythmias (e.g., hypokalemia, hypomagnesemia, bradycardia, acute myocardial infarction or uncompensated heart failure) or increased exposure to fluoxetine (e.g., hepatic impairment), or concomitant use with medicinal products known to induce<br />QT prolongation and/or torsade de pointes (see section 4.5). If patients with stable cardiac disease are treated, an ECG review should be considered before treatment is started.</p><p>If signs of cardiac arrhythmia occur during treatment with fluoxetine, the treatment should be withdrawn and an ECG should be performed.</p><p><u>Irreversible, non-selective monoamine oxidase inhibitors (e.g. iproniazid)</u></p><p>Some cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with an irreversible, non-selective monoamine oxidase inhibitor (MAOI). These cases presented with features resembling serotonin syndrome (which may be confounded with (or diagnosed as) neuroleptic malignant syndrome). Cyproheptadine or dantrolene may benefit patients experiencing such reactions. Symptoms of a drug interaction with a MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma. Therefore, fluoxetine is contra-indicated in combination with an irreversible, non-selective MAOI (see section 4.3). Because of the two weeks-lasting effect of the latter, treatment of fluoxetine should only be started 2 weeks after discontinuation of an irreversible, non-selective MAOI. Similarly, at least 5 weeks should elapse after discontinuing fluoxetine treatment before starting an irreversible, non-selective MAOI.</p><p><u>Serotonin syndrome or neuroleptic malignant syndrome-like events</u></p><p>On rare occasions development of a serotonin syndrome or neuroleptic malignant syndrome-like events have been reported in association with treatment of fluoxetine, particularly when given in combination with other serotonergic (among others L-tryptophan) and/or neuroleptic drugs (see section 4.5). As these syndromes may result in potentially life-threatening conditions, treatment with fluoxetine should be discontinued if such events (characterized by clusters of symptoms such as hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes including confusion, irritability, extreme agitation progressing to delirium and coma) occur and supportive symptomatic treatment should be initiated.</p><p><u>Mania</u></p><p>Antidepressants should be used with caution in patients with a history of mania/hypomania. As with all antidepressants, fluoxetine should be&nbsp; discontinued in any patient entering a manic phase.</p><p><u>Haemorrhage</u></p><p>There have been reports of cutaneous bleeding abnormalities such as ecchymosis and purpura with SSRI&#39;s. Ecchymosis has been reported as an infrequent event during treatment with fluoxetine. Other haemorrhagic manifestations (e.g., gynaecological haemorrhages, gastrointestinal bleedings and other cutaneous or mucous bleedings) have been reported rarely. Caution is advised in patients taking SSRI&#39;s, particularly in concomitant use with oral anticoagulants, drugs known to affect platelet function (e.g. atypical antipsychotics such as clozapine, phenothiazines, most TCA&#39;s, aspirin, NSAID&#39;s) or other drugs that may increase risk of bleeding as well as in patients with a history of bleeding disorders (see section 4.5).</p><p><u>Seizures</u></p><p>Seizures are a potential risk with antidepressant drugs. Therefore, as with other antidepressants, fluoxetine should be introduced cautiously in patients who have a history of seizures. Treatment should be discontinued in any patient who develops seizures or where there is an increase in seizure frequency. Fluoxetine should be avoided in patients with unstable seizure disorders/epilepsy and patients with controlled epilepsy should be carefully monitored (see section 4.5).</p><p><u>Electroconvulsive Therapy (ECT)</u></p><p>There have been rare reports of prolonged seizures in patients on fluoxetine receiving ECT treatment, therefore caution is advisable.</p><p><u>Tamoxifen</u><br />Fluoxetine, a potent inhibitor of CYP2D6, may lead to reduced concentrations of endoxifen, one of the most important active metabolites of tamoxifen. Therefore, fluoxetine should whenever possible be avoided during tamoxifen treatment (see section 4.5).</p><p><br /><u>Akathisia/psychomotor restlessness</u><br />The use of fluoxetine has been associated with the development of akathisia, characterised by a subjectively unpleasant or distressing restlessness and need to move often accompanied by an inability to sit or stand still. This is most likely to occur within the first few weeks of treatment. In patients who develop these symptoms, increasing the dose may be detrimental.</p><p><u>Diabetes</u><br />In patients with diabetes, treatment with an SSRI may alter glycaemic control. Hypoglycaemia has occurred during therapy with fluoxetine and hyperglycaemia has developed following discontinuation. Insulin and/or oral hypoglycaemic dosage may need to be adjusted.</p><p><u>Hepatic/Renal Function </u></p><p>Fluoxetine is extensively metabolized by the liver and excreted by the kidneys. A lower dose, e.g., alternate day dosing, is recommended in patients with significant hepatic dysfunction. When given fluoxetine 20 mg/day for 2 months, patients with severe renal failure (GFR &lt;10 ml/min) requiring dialysis showed no difference in plasma levels of fluoxetine or norfluoxetine compared to controls with normal renal function.</p><p><br /><u>Rash and allergic reactions</u><br />Rash, anaphylactoid events and progressive systemic events, sometimes serious (involving skin, kidney, liver or lung) have been reported. Upon the appearance of rash or of other allergic phenomena for which an alternative aetiology cannot be identified, fluoxetine should be discontinued.</p><p><br /><u>Weight loss</u><br />Weight loss may occur in patients taking fluoxetine, but it is usually proportional to baseline body weight.</p><p><br /><u>Withdrawal symptoms seen on discontinuation of SSRI treatment</u><br />Withdrawal symptoms when treatment is discontinued are common, particularly if discontinuation is abrupt (see section 4.8). In clinical trials, adverse events seen on treatment discontinuation occurred in approximately 60% of patients in both the fluoxetine and placebo groups. Of these adverse events, 17% in the fluoxetine group and 12% in the placebo group were severe in nature. The risk of withdrawal symptoms may be dependent on several factors, including the duration and dose of<br />therapy and the rate of dose reduction. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremor, and headache are the most commonly reported reactions. Generally, these symptoms are mild to moderate; however, in some patients they may be severe in intensity. They usually occur within the first few days of discontinuing treatment. Generally, these symptoms are self-limiting and usually resolve within 2 weeks, though in some individuals they may be prolonged (2-3 months or more). It is therefore advised that FLOZAK should be gradually tapered when discontinuing treatment over a period of at least one to two weeks, according to the patient&#39;s needs (see Withdrawal symptoms seen on discontinuation of FLOZAK, section 4.2).</p><p><br /><u>Mydriasis</u><br />Mydriasis has been reported in association with fluoxetine; therefore, caution should be used when prescribing fluoxetine in patients with raised intraocular pressure or those at risk of acute narrow-angle glaucoma.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Half-life: The long elimination half-lives of both fluoxetine and norfluoxetine should be borne in mind (see section 5.2) when considering pharmacodynamic or pharmacokinetic drug interactions (e.g., when switching from fluoxetine to other antidepressants).<br /><em><u>Contra-indicated combinations</u></em><br /><em>Irreversible, non-selective monoamine oxidase inhibitors </em>(e.g. iproniazid): Some cases of serious and sometimes fatal reactions have been reported in patients receiving an SSRI in combination with an irreversible, non-selective monoamine oxidase inhibitor (MAOI).<br />These cases presented with features resembling serotonin syndrome (which may be confounded with [or diagnosed as] neuroleptic malignant syndrome). Cyproheptadine or dantrolene may benefit patients experiencing such reactions. Symptoms of a drug interaction with a MAOI include: hyperthermia, rigidity, myoclonus, autonomic instability with possible rapid fluctuations of vital signs, mental status changes that include confusion, irritability and extreme agitation progressing to delirium and coma.<br />Therefore, fluoxetine is contra-indicated in combination with an irreversible, non-selective MAOI (see section 4.3). Because of the two weeks-lasting effect of the latter, treatment of fluoxetine should only be started 2 weeks after discontinuation of an irreversible, non-selective MAOI. Similarly, at least 5 weeks should elapse after discontinuing fluoxetine treatment before starting an irreversible, non-selective MAOI. Metoprolol used in cardiac failure: risk of metoprolol adverse events, including excessive bradycardia, may be increased because of an inhibition of its metabolism by fluoxetine (see section 4.3).</p><p><em><u>Not recommended combinations</u></em><br />Tamoxifen: Pharmacokinetic interaction between CYP2D6 inhibitors and tamoxifen, showing a 65-75 % reduction in plasma levels of one of the more active forms of the tamoxifen, i.e. endoxifen, has been reported in the literature. Reduced efficacy of tamoxifen has been reported with concomitant usage of some SSRI antidepressants in some studies. As a reduced effect of tamoxifen cannot be excluded, co-administration with potent CYP2D6 inhibitors (including fluoxetine) should whenever possible be avoided (see section 4.4).<br />Alcohol: In formal testing, fluoxetine did not raise blood alcohol levels or enhance the effects of alcohol. However, the combination of SSRI treatment and alcohol is not advisable.<br />MAOI-A including linezolid and methylthioninium chloride (methylene blue): Risk of serotonin syndrome including diarrhoea, tachycardia, sweating, tremor, confusion or coma. If the concomitant use of these active substances with fluoxetine cannot be avoided, close clinical monitoring should be undertaken and the concomitant agents should be initiated at the lower recommended doses (see section 4.4). Mequitazine: risk of mequitazine adverse events (such as QT prolongation) may be increased because of an inhibition of its metabolism by fluoxetine.</p><p><em><u>Combinations requiring caution</u></em><br />Phenytoin: Changes in blood levels have been observed when combined with fluoxetine. In some cases manifestations of toxicity have occurred. Consideration should be given to using conservative titration schedules of the concomitant drug and to monitoring clinical status. Serotoninergic drugs (lithium, tramadol, triptans, tryptophan, selegiline (MAOI-B), St. John&#39;s Wort (Hypericum perforatum)): There have been reports of mild serotonin syndrome when SSRIs were given with drugs also having a serotoninergic effect. Therefore, the concomitant use of fluoxetine with these drugs should be undertaken with caution, with closer and more frequent clinical monitoring (see section 4.4). QT interval prolongation: Pharmacokinetic and pharmacodynamic studies between fluoxetine and other medicinal products that prolong the QT interval have not been performed. An additive effect of fluoxetine and these medicinal products cannot be excluded. Therefore, co-administration of fluoxetine with medicinal products that prolong the QT interval, such as Class IA and III antiarrhythmics, antipsychotics (e.g. phenothiazine derivatives, pimozide, haloperidol), tricyclic antidepressants, certain antimicrobial agents (e.g. sparfloxacin, moxifloxacin, erythromycin IV, pentamidine), anti-malaria treatment particularly halofantrine, certain antihistamines (astemizole, mizolastine), should be used with caution (see sections 4.4, 4.8 and 4.9). Drugs affecting haemostasis (oral anticoagulants, whatever their mechanism, platelets antiaggregants including aspirin and NSAIDs): risk of increased bleeding. Clinical monitoring, and more frequent monitoring of INR with oral anticoagulants, should be made. A dose adjustment during the fluoxetine treatment and after its discontinuation may be suitable (see sections 4.4 and 4.8).<br />Cyproheptadine: There are individual case reports of reduced antidepressant activity of fluoxetine when used in combination with cyproheptadine.<br />Drugs inducing hyponatremia: Hyponatremia is an undesirable effect of fluoxetine. Use in combination with other agents associated with hyponatremia (e.g. diuretics, desmopressin, carbamazepine and oxcarbazepine) may lead to an increased risk (see section 4.8). Drugs lowering the epileptogenic threshold: Seizures are an undesirable effect of fluoxetine. Use in combination with other agents which may lower the seizure threshold (for example, TCAs, other SSRIs,<br />phenothiazines, butyrophenones, mefloquine, chloroquine, bupropion, tramadol) may lead to an increased risk. Other drugs metabolised by CYP2D6: Fluoxetine is a strong inhibitor of CYP2D6 enzyme, therefore concomitant therapy with drugs also metabolised by this enzyme system may lead to drug interactions, notably those having a narrow therapeutic index (such as flecainide, propafenone and nebivolol) and those that are titrated, but also with atomoxetine, carbamazepine, tricyclic antidepressants and risperidone. They should be initiated at or adjusted to the low end of their dose range. This may also apply if fluoxetine has been taken in the previous 5 weeks.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u><strong>Pregnancy</strong></u><br />Some epidemiological studies suggest an increased risk of cardiovascular defects associated with the use of fluoxetine during the first trimester. The mechanism is unknown. Overall the data suggest that the risk of having an infant with a cardiovascular defect following maternal fluoxetine exposure is in the region of 2/100 compared with an expected rate for such defects of approximately 1/100 in the general population. Epidemiological data have suggested that the use of SSRIs in pregnancy, particularly in late pregnancy, may increase the risk of persistent pulmonary hypertension in the newborn (PPHN). The observed risk was approximately 5 cases per 1000 pregnancies. In the general population 1 to 2 cases of PPHN per 1000 pregnancies occur. Fluoxetine should not be used during pregnancy unless the clinical condition of the woman requires treatment with fluoxetine and justifies the potential risk to the foetus. Abrupt discontinuation of therapy should be avoided during pregnancy (see section 4.2 &ldquo;Posology and method of administration&rdquo;). If fluoxetine is used during pregnancy, caution should be exercised, especially during late pregnancy or just prior to the onset of labour since some other effects have been reported in neonates: irritability, tremor, hypotonia, persistent crying, difficulty in sucking or in sleeping. These symptoms may indicate either serotonergic effects or a withdrawal syndrome. The time to occur and the duration of these symptoms may be related to the long half-life of fluoxetine (4-6 days) and its active metabolite, norfluoxetine (4-16 days).<br /><u><strong>Breast-feeding</strong></u><br />Fluoxetine and its metabolite norfluoxetine, are known to be excreted in human breast milk. Adverse events have been reported in breastfeeding infants. If treatment with fluoxetine is considered necessary, discontinuation of breastfeeding should be considered; however, if breastfeeding is continued, the lowest effective dose of fluoxetine should be prescribed.<br /><u><strong>Fertility</strong></u><br />Animal data have shown that fluoxetine may affect sperm quality (see section 5.3). Human case reports with some SSRI&#39;s have shown that an effect on sperm quality is reversible. Impact on human fertility has not been observed so far.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>FLOZAK has no or negligible influence on the ability to drive and use machines. Although fluoxetine has been shown not to affect psychomotor performance in healthy volunteers, any psychoactive drug may impair judgement or skills. Patients should be advised to avoid driving a car or operating hazardous machinery until they are reasonably certain that their performance is not affected.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>a. Summary of the safety profile</u><br />The most commonly reported adverse reactions in patients treated with fluoxetine were headache, nausea, insomnia, fatigue and diarrhoea. Undesirable effects may decrease in intensity and frequency with continued treatment and do not generally lead to cessation of therapy.</p><p><u>b. Tabulated list of adverse reactions</u></p><p>The table below gives the adverse reactions observed with fluoxetine treatment in adult and paediatric populations. Some of these adverse reactions are in common with other SSRIs. The following frequencies have been calculated from clinical trials in adults (n = 9297) and from spontaneous reporting.<br />Frequency estimate: Very common (&ge;1/10), common (&ge;1/100 to &lt;1/10), uncommon (&ge;1/1,000 to &lt;1/100), rare (&ge;1/10,000 to &lt;1/1,000).</p><table border="1" cellspacing="0" cellpadding="0" style="width:0px"><tbody><tr><td style="vertical-align:top"><p><strong>Very Common</strong></p></td><td style="vertical-align:top"><p><strong>Common</strong></p></td><td style="vertical-align:top"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top"><p><strong>Rare</strong></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Blood and lymphatic system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Thrombocytopenia</p><p>Neutropenia</p><p>Leucopenia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Immune system disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Anaphylactic reaction</p><p>Serum sickness</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Endocrine disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Inappropriate antidiuretic hormone secretion</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Metabolism and nutrition disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Decreased appetite<sup>1</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Hyponatraemia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Psychiatric disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Insomnia<sup>2</sup></p></td><td style="vertical-align:top"><p>Anxiety</p><p>Nervousness</p><p>Restlessness</p><p>Tension</p><p>Libido decreased<sup>3</sup></p><p>Sleep disorder</p><p>Abnormal dreams<sup>4</sup></p></td><td style="vertical-align:top"><p>Depersonalisation</p><p>Elevated mood</p><p>Euphoric mood</p><p>Thinking abnormal</p><p>Orgasm abnormal<sup>5</sup></p><p>Bruxism</p><p>Suicidal thoughts and behaviour&nbsp;<sup>6</sup></p></td><td style="vertical-align:top"><p>Hypomania</p><p>Mania</p><p>Hallucinations</p><p>Agitation</p><p>Panic attacks</p><p>Confusion</p><p>Dysphemia</p><p>Aggression</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Nervous system disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Headache</p></td><td style="vertical-align:top"><p>Disturbance in attention</p><p>Dizziness</p><p>Dysgeusia</p><p>Lethargy</p><p>Somnolence<sup>7</sup></p><p>Tremor</p></td><td style="vertical-align:top"><p>Psychomotor hyperactivity</p><p>Dyskinesia</p><p>Ataxia</p><p>Balance disorder</p><p>Myoclonus</p><p>Memory impairment</p></td><td style="vertical-align:top"><p>Convulsion</p><p>Akathisia</p><p>Buccoglossal syndrome</p><p>Serotonin syndrome</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Eye disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Vision blurred</p></td><td style="vertical-align:top"><p>Mydriasis</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Ear and labyrinth disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Tinnitus</p></td><td style="vertical-align:top">&nbsp;</td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Cardiac disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Palpitations</p><p>Electrocardiogram QT prolonged (QTcF &ge;450 msec)<sup>8</sup></p></td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Ventricular arrhythmia including torsades de pointes</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Vascular disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Flushing<sup>9</sup></p></td><td style="vertical-align:top"><p>Hypotension</p></td><td style="vertical-align:top"><p>Vasculitis</p><p>Vasodilatation</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Respiratory, thoracic and mediastinal disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Yawning</p></td><td style="vertical-align:top"><p>Dyspnoea</p><p>Epistaxis</p></td><td style="vertical-align:top"><p>Pharyngitis</p><p>Pulmonary events (inflammatory processes of varying histopathology and/or fibrosis)<sup>10</sup></p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Gastrointestinal disorders</em></p></td></tr><tr><td style="vertical-align:top"><p>Diarrhoea</p><p>Nausea</p></td><td style="vertical-align:top"><p>Vomiting</p><p>Dyspepsia</p><p>Dry mouth</p></td><td style="vertical-align:top"><p>Dysphagia</p><p>Gastrointestinal haemorrhage<sup>11</sup></p></td><td style="vertical-align:top"><p>Oesophageal pain</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Hepato</em>&nbsp;<em>-biliary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Idiosyncratic hepatitis</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Skin and subcutaneous tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Rash<sup>12</sup></p><p>Urticaria</p><p>Pruritus</p><p>Hyperhidrosis</p></td><td style="vertical-align:top"><p>Alopecia</p><p>Increased tendency to bruise</p><p>Cold sweat</p></td><td style="vertical-align:top"><p>Angioedema</p><p>Ecchymosis</p><p>Photosensitivity reaction</p><p>Purpura</p><p>Erythema multiforme</p><p>Stevens-Johnson syndrome</p><p>Toxic Epidermal Necrolysis (Lyell Syndrome)</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Musculoskeletal and connective tissue disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Arthralgia</p></td><td style="vertical-align:top"><p>Muscle twitching</p></td><td style="vertical-align:top"><p>Myalgia</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Renal and urinary disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Frequent urination<sup>13</sup></p></td><td style="vertical-align:top"><p>Dysuria</p></td><td style="vertical-align:top"><p>Urinary retention</p><p>Micturition disorder</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Reproductive system and breast disorders</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Gynaecological bleeding<sup>14</sup></p><p>Erectile dysfunction</p><p>Ejaculation disorder<sup>15</sup></p></td><td style="vertical-align:top"><p>Sexual dysfunction</p></td><td style="vertical-align:top"><p>Galactorrhoea</p><p>Hyperprolactinaemia</p><p>Priapism</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>General disorders and administration site conditions</em></p></td></tr><tr><td style="vertical-align:top"><p>Fatigue<sup>16</sup></p></td><td style="vertical-align:top"><p>Feeling jittery</p><p>Chills</p></td><td style="vertical-align:top"><p>Malaise</p><p>Feeling abnormal</p><p>Feeling cold</p><p>Feeling hot</p></td><td style="vertical-align:top"><p>Mucosal haemorrhage</p></td></tr><tr><td colspan="4" style="vertical-align:top"><p><em>Investigations</em></p></td></tr><tr><td style="vertical-align:top">&nbsp;</td><td style="vertical-align:top"><p>Weight decreased</p></td><td style="vertical-align:top"><p>Transaminases increased</p><p>Gamma-glutamyltransferase increased</p></td><td style="vertical-align:top">&nbsp;</td></tr></tbody></table><p><sup>1</sup>&nbsp;Includes anorexia</p><p><sup>2</sup>&nbsp;Includes early morning awakening, initial insomnia, middle insomnia</p><p><sup>3&nbsp;</sup>Includes loss of libido</p><p><sup>4</sup>&nbsp;Includes nightmares</p><p><sup>5</sup>&nbsp;Includes anorgasmia</p><p><sup>6&nbsp;</sup>Includes completed suicide, depression suicidal, intentional self-injury, self-injurious ideation, suicidal behaviour, suicidal ideation, suicide attempt, morbid thoughts, self-injurious behaviour. These symptoms may be due to underlying disease</p><p><sup>7</sup>&nbsp;Includes hypersomnia, sedation</p><p><sup>8</sup>&nbsp;Based on ECG measurements from clinical trials</p><p><sup>9</sup>&nbsp;Includes hot flush</p><p><sup>10</sup>&nbsp;Includes atelectasis, interstitial lung disease, pneumonitis</p><p><sup>11</sup>&nbsp;Includes most frequently gingival bleeding, haematemesis, haematochezia, rectal haemorrhage, diarrhoea haemorrhagic, melaena, and gastric ulcerhaemorrhage</p><p><sup>12</sup>&nbsp;Includes erythema, exfoliative rash, heat rash, rash, rash erythematous, rash follicular, rash generalized, rash macular, rash macular-papular, rash morbilliform, rash papular, rash pruritic, rash vesicular, umbilical erythema rash</p><p><sup>13</sup>&nbsp;Includes pollakiuria</p><p><sup>14</sup>&nbsp;Includes cervix haemorrhage, uterine dysfunction, uterine bleeding, genital haemorrhage, menometrorhagia, menorrhagia, metrorrhagia, polymenorrhea, postmenopausal haemorrhage, uterine haemorrhage, vaginal haemorrhage</p><p><sup>15</sup>&nbsp;Includes ejaculation failure, ejaculation dysfunction, premature ejaculation, ejaculation delayed, retrograde ejaculation</p><p><sup>16</sup>&nbsp;Includes asthenia</p><p>&nbsp;</p><p>c.&nbsp;<u>Description of selected adverse reactions</u></p><p><em>Suicide/suicidal thoughts or clinical worsening</em>: Cases of suicidal ideation and suicidal behaviour have been reported during fluoxetine therapy or early after treatment discontinuation (see section 4.4).</p><p><em>Bone fractures:</em>&nbsp;Epidemiological studies, mainly conducted in patients 50 years of age and older, show an increased risk of bone fractures in patients receiving SSRIs and TCAs. The mechanism leading to the risk is unknown.</p><p><em>Withdrawal symptoms seen on discontinuation of fluoxetine treatments:&nbsp;</em>Discontinuation of fluoxetine commonly leads to withdrawal symptoms. Dizziness, sensory disturbances (including paraesthesia), sleep disturbances (including insomnia and intense dreams), asthenia, agitation or anxiety, nausea and/or vomiting, tremor and headache are the most commonly reported reactions. Generally these events are mild to moderate and are self-limiting, however, in some patients they may be severe and/or prolonged (see section 4.4). It is therefore advised that when FLOZAK treatment is no longer required, gradual discontinuation by dose tapering should be carried out (see sections 4.2 and 4.4).</p><p>&nbsp;</p><p>d.&nbsp;<u>Paediatric population (see sections 4.4 and 5.1)</u></p><p>Adverse reactions that have been observed specifically or with a different frequency in this population are described below. Frequencies for these events are based on paediatric clinical trial exposures (n = 610).</p><p>In paediatric clinical trials, suicide-related behaviours (suicide attempt and suicidal thoughts), hostility (the events reported were: anger, irritability, aggression, agitation, activation syndrome), manic reactions, including mania and hypomania (no prior episodes reported in these patients) and epistaxis, were commonly reported and were more frequently observed among children and adolescents treated with antidepressants compared to those treated with placebo.</p><p>Isolated cases of growth retardation have been reported from clinical use (See also section 5.1).</p><p>In paediatric clinical trials, fluoxetine treatment was also associated with a decrease in alkaline phosphatase levels.</p><p>Isolated cases of adverse events potentially indicating delayed sexual maturation or sexual dysfunction have been reported from paediatric clinical use (see also section 5.3).</p><p>&nbsp;</p><p>To report any side effects:</p><p>The National Pharmacovigilance Centre (NPC):</p><p>Fax: +966-11-205-7662</p><p>SFDA Call Center: 19999</p><p>E-mail: npc.drug@sfda.gov.sa</p><p>Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Symptoms</u></p><p>Cases of overdose of fluoxetine alone usually have a mild course. Symptoms of overdose have included nausea, vomiting, seizures, cardiovascular dysfunction ranging from asymptomatic arrhythmias (including nodal rhythm and ventricular arrhythmias) or ECG changes indicative of QTc prolongation to cardiac arrest (including very rare cases of Torsades de Pointes), pulmonary dysfunction, and signs of altered CNS status ranging from excitation to coma. Fatality attributed to overdose of fluoxetine alone has been extremely rare.</p><p><u>Management</u></p><p>Cardiac and vital signs monitoring are recommended, along with general symptomatic and supportive measures. No specific antidote is known.</p><p>Forced diuresis, dialysis, haemoperfusion, and exchange transfusion are unlikely to be of benefit. Activated charcoal, which may be used with sorbitol, may be as or more effective than emesis or lavage. In managing overdosage, consider the possibility of multiple drug involvement. An extended time for close medical observation may be needed in patients who have taken excessive quantities of a tricyclic antidepressant if they are also taking, or have recently taken, fluoxetine.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><em>Pharmacotherapeutic&nbsp;group:</em>&nbsp;Selective serotonin reuptake inhibitors.&nbsp;<em>ATC code:</em>&nbsp;N06A B03.</p><p><u>Mechanism of action</u></p><p>Fluoxetine is a selective inhibitor of serotonin reuptake, and this probably accounts for the mechanism of action. Fluoxetine has practically no affinity to other receptors such as &alpha;<sub>1</sub>-, &alpha;<sub>2</sub>-, and &beta;-adrenergic; serotonergic; dopaminergic; histaminergic<sub>1</sub>; muscarinic; and GABA receptors.</p><p><u>Clinical efficacy and safety</u></p><p><em>Major depressive episodes:</em>&nbsp;Clinical trials in patients with major depressive episodes have been conducted versus placebo and active controls. Fluoxetine has been shown to be significantly more effective than placebo, as measured by the Hamilton Depression Rating Scale (HAM-D). In these studies, Fluoxetine produced a significantly higher rate of response (defined by a 50% decrease in the HAM-D score) and remission compared to placebo.</p><p><em>Dose response:</em>&nbsp;In the fixed-dose studies of patients with major depression there is a flat dose response curve, providing no suggestion of advantage in terms of efficacy for using higher than the recommended doses. However, it is clinical experience that uptitrating might be beneficial for some patients.</p><p><em>Obsessive-compulsive disorder:</em>&nbsp;In short-term trials (under 24 weeks), fluoxetine was shown to be significantly more effective than placebo. There was a therapeutic effect at 20mg/day, but higher doses (40 or 60mg/day) showed a higher response rate. In long-term studies (three short-term studies extension phase and a relapse prevention study), efficacy has not been shown.</p><p><em>Bulimia nervosa:</em>&nbsp;In short-term trials (under 16 weeks), in out-patients fulfilling DSM-III-R-criteria for bulimia nervosa, fluoxetine 60mg/day was shown to be significantly more effective than placebo for the reduction of bingeing, vomiting and purging activities. However, for long-term efficacy no conclusion can be drawn.</p><p><em>Pre-Menstrual Dysphoric Disorder</em>: Two placebo-controlled studies were conducted in patients meeting Pre-Menstrual Dysphoric Disorder (PMDD) diagnostic criteria according to DSM-IV. Patients were included if they had symptoms of sufficient severity to impair social and occupational function and relationships with others. Patients using oral contraceptives were excluded. In the first study of continuous 20mg daily dosing for 6 cycles, improvement was observed in the primary efficacy parameter (irritability, anxiety and dysphoria). In the second study, with intermittent luteal phase dosing (20mg daily for 14 days) for 3 cycles, improvement was observed in the primary efficacy parameter (Daily Record of Severity of Problems score). However, definitive conclusions on efficacy and duration of treatment cannot be drawn from these studies.</p><p><u>Paediatric population</u></p><p><em>Major depressive episodes:</em>&nbsp;Clinical trials in children and adolescents aged 8 years and above have been conducted versus placebo. Fluoxetine, at a dose of 20mg, has been shown to be significantly more effective than placebo in two short-term pivotal studies, as measured by the reduction of Childhood Depression Rating Scale-Revised (CDRS-R) total scores and Clinical Global Impression of Improvement (CGI-I) scores. In both studies, patients met criteria for moderate to severe MDD (DSM-III or DSM-IV) at three different evaluations by practising child psychiatrists. Efficacy in the fluoxetine trials may depend on the inclusion of a selective patient population (one that has not spontaneously recovered within a period of 3-5 weeks and whose depression persisted in the face of considerable attention). There is only limited data on safety and efficacy beyond 9 weeks. In general, efficacy of fluoxetine was modest. Response rates (the primary endpoint, defined as a 30% decrease in the CDRS-R score) demonstrated a statistically significant difference in one of the two pivotal studies (58% for fluoxetine versus 32% for placebo,&nbsp;<em>P</em>&nbsp;= 0.013; and 65% for fluoxetine versus 54% for placebo,&nbsp;<em>P</em>&nbsp;= 0.093). In these two studies, the mean absolute changes in CDRS-R from baseline to endpoint were 20 for fluoxetine versus 11 for placebo,&nbsp;<em>P</em>&nbsp;= 0.002; and 22 for fluoxetine versus 15 for placebo,&nbsp;<em>P</em>&nbsp;&lt;0.001.</p><p><em>Effects on growth, see sections 4.4 and 4.8:&nbsp;</em>After 19 weeks of treatment, paediatric subjects treated with fluoxetine in a clinical trial gained an average of 1.1 cm less in height (p=0.004) and 1.1 kg less in weight (p=0.008) than subjects treated with placebo.</p><p>In a retrospective matched control observational study with a mean of 1.8 years of exposure to fluoxetine, paediatric subjects treated with fluoxetine had no difference in growth adjusted for expected growth in height from their matched, untreated controls (0.0 cm, p=0.9673).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Absorption</u></p><p>Fluoxetine is well absorbed from the gastro-intestinal tract after oral administration. The bioavailability is not affected by food intake.</p><p><u>Distribution</u></p><p>Fluoxetine is extensively bound to plasma proteins (about 95%) and it is widely distributed (volume of distribution: 20-40 L/kg). Steady-state plasma concentrations are achieved after dosing for several weeks. Steady-state concentrations after prolonged dosing are similar to concentrations seen at 4 to 5 weeks.</p><p><u>Biotransformation</u></p><p>Fluoxetine has a non-linear pharmacokinetic profile with first-pass liver effect. Maximum plasma concentration is generally achieved 6 to 8 hours after administration. Fluoxetine is extensively metabolised by the polymorphic enzyme CYP2D6. Fluoxetine is primarily metabolised by the liver to the active metabolite norfluoxetine (desmethylfluoxetine), by desmethylation.</p><p><u>Elimination</u></p><p>The elimination half-life of fluoxetine is 4 to 6 days and for norfluoxetine 4 to 16 days. These long half-lives are responsible for persistence of the drug for 5-6 weeks after discontinuation. Excretion is mainly (about 60%) via the kidney. Fluoxetine is secreted into breast milk.</p><p><em>Special populations</em></p><p><u>Elderly</u>: Kinetic parameters are not altered in healthy elderly when compared to younger subjects.</p><p><u>Paediatric population</u>: The mean fluoxetine concentration in children is approximately 2-fold higher than that observed in adolescents and the mean norfluoxetine concentration 1.5-fold higher. Steady-state plasma concentrations are dependent on body weight and are higher in lower-weight children (see section 4.2). As in adults, fluoxetine and norfluoxetine accumulated extensively following multiple oral dosing; steady-state concentrations were achieved within 3 to 4 weeks of daily dosing.</p><p><u>Hepatic insufficiency</u>: In case of hepatic insufficiency (alcoholic cirrhosis), fluoxetine and norfluoxetine half-lives are increased to 7 and 12 days, respectively. A lower or less frequent dose should be considered.</p><p><u>Renal insufficiency</u>: After single-dose administration of fluoxetine in patients with mild, moderate, or complete (anuria) renal insufficiency, kinetic parameters have not been altered when compared to healthy volunteers. However, after repeated administration, an increase in steady-state plateau of plasma concentrations may be observed.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There is no evidence of carcinogenicity or mutagenicity from&nbsp;<em>in vitro</em>&nbsp;or animal studies.</p><p><strong><em>Adult animal studies</em></strong></p><p>In a 2-generation rat reproduction study, fluoxetine did not produce adverse effects on the mating or fertility of rats, was not teratogenic, and did not affect growth, development, or reproductive parameters of the offspring.</p><p>The concentrations in the diet provided doses approximately equivalent to 1.5, 3.9, and 9.7 mg fluoxetine/kg body weight.</p><p>Male mice treated daily for 3 months with fluoxetine in the diet at a dose approximately equivalent to 31 mg/kg showed a decrease in testis weight and hypospermatogenesis. However, this dose level exceeded the maximum-tolerated dose (MTD) as significant signs of toxicity were seen.</p><p><strong><em>Juvenile animal studies</em></strong></p><p>In a juvenile toxicology study in CD rats, administration of 30 mg/kg/day of fluoxetine hydrochloride on postnatal days 21 to 90 resulted in irreversible testicular degeneration and necrosis, epididymal epithelial vacuolation, immaturity and inactivity of the female reproductive tract and decreased fertility. Delays in sexual maturation occurred in males (10 and 30 mg/kg/day) and females (30 mg/kg/day). The significance of these findings in humans is unknown. Rats administered 30 mg/kg also had decreased femur lengths compared with controls and skeletal muscle degeneration, necrosis and regeneration. At 10 mg/kg/day, plasma levels achieved in animals were approximately 0.8 to 8.8 fold (fluoxetine) and 3.6 to 23.2 fold (norfluoxetine) those usually observed in paediatric patients. At 3 mg/kg/day, plasma levels achieved in animals were approximately 0.04 to 0.5 fold (fluoxetine) and 0.3 to 2.1 fold (norfluoxetine) those usually achieved in paediatric patients.</p><p>A study in juvenile mice has indicated that inhibition of the serotonin transporter prevents the accrual of bone formation. This finding would appear to be supported by clinical findings.The reversibility of this effect has not been established.</p><p>Another study in juvenile mice (treated on postnatal days 4 to 21) has demonstrated that inhibition of the serotonin transporter had long-lasting effects on the behaviour of the mice. There is no information on whether the effect was reversible. The clinical relevance of this finding has not been established.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Maize Starch (1500)</p><p>Purified Talc</p><p>Colloidal Anhydrous Silica</p><p>Magnesiun Stearate</p><p>Capsule Shells (size 2) RP12</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Three years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 30&deg;C</p><p>In use instructions: use during one month after first opening.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>White plastic (Polypropylene) Securitainer with white Plastic (LDPE) Cap containing 30 Capsules.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Marketing Authorisation Holder and Manufacturer
Medical and Cosmetic Products Company Ltd. (Riyadh Pharma)
P.O.Box 442, Riyadh 11411
Fax: +966 11 265 0505
Email: contact@riyadhpharma.com
For any information about this medicinal product, please contact the local representative of marketing
authorisation holder:
Saudi Arabia
Marketing department
Riyadh
Tel: +966 11 265 0111
Email: marketing@riyadhpharma.com
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                11/2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>